WO2002085385A2 - Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa - Google Patents
Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa Download PDFInfo
- Publication number
- WO2002085385A2 WO2002085385A2 PCT/CA2002/000547 CA0200547W WO02085385A2 WO 2002085385 A2 WO2002085385 A2 WO 2002085385A2 CA 0200547 W CA0200547 W CA 0200547W WO 02085385 A2 WO02085385 A2 WO 02085385A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimicrobial
- silver
- kit
- metal
- nanocrystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
- A61L17/145—Coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/10—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/452—Lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/63—Crystals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31855—Of addition polymer from unsaturated monomers
Definitions
- the invention relates to the use of antimicrobial or noble metals for administration to mucosal membranes.
- Mucosal membranes are the epithelial membranes which line the oral cavity, the nasal, bronchial, pulmonary, trachea and pharynx airways, the otic and ophthalmic surfaces, the urogenital system, including the prostate, the reproductive system and the gastrointestinal tract including the colon and rectal surfaces.
- Mucosal membrane includes the surface membranes or cell structures of the mucosal membrane at a subject's targeted site. Mucosal membranes represent the first portal of entry for many diseases.
- RNA or DNA viruses bacterial (gram positive and gram negative, whether aerobic, facultative, or anaerobic), fungal, or algal origin (all of which are exemplary of sources of microbial infection of the mucosal membranes) are: Vibrio cholerae, enterotoxigenic Escherichia coli, Rotavirus, Clostridium difficile, Shigella species, Salmonella typhi, parainfluenza virus, influenza virus, Streptococcus pneumoniae, Borellia burgdorferi, HIV, Streptococcus mutans, Plasmodium falciparum, Staphylococcus aureus, Pseudomonas aeruginosa, rabies virus, Epstein-Barr virus, Herpes simplex virus, type I and ⁇ .
- Mucosal membranes are also the subject of many disorders and diseases which are not strictly microbial in nature, for instance cystic fibrosis, prostatitis and digestive disorders.
- the antimicrobial metal is preferably formed with atomic disorder at the nanocrystalline level, that is with a very fine, nanocrystalline grain size.
- the nanocrystalline antimicrobial metals formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal (example clusters of Ag° or Ag + /Ag°), which are responsible for the surprisingly enhanced antimicrobial activity and the surprising presence of the anti- inflammatory activity in the treatment of mucosal membranes, compared with other known antimicrobials such as silver salts (ex. silver nitrate), silver zeolites which release only Ag + , or silver metal and silver oxide which have only minor solubility.
- Clusters are known to be small groups of atoms, ions or the like, as described by R. P.
- clusters are believed to contain less than the 14 atoms of a normal face centered cubic crystal lattice form of silver.
- the invention thus may be used to deliver nanocrystalline antimicrobial or, more preferably, noble metals formed with atomic disorder across mucosal membranes including without limitation gastrointestinal epithelial tissue, lung epithelial tissue and other mucosal surfaces including oral surfaces, nasal surfaces, sinus surfaces, pharynx surfaces, trachea! surfaces, esophageal surfaces, vaginal surfaces, rectal surfaces, colon surfaces, otic and ophthalmic surfaces,
- the invention also provides treatment for respiratory disorders, whether infectious, inflammatory or immunologic in origin, including without limitation emphysema, chronic bronchitis, asthma, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia and cystic fibrosis, with the use of aerosols, mists or sprays of the nanocrystalline antimicrobial metals.
- respiratory disorders whether infectious, inflammatory or immunologic in origin, including without limitation emphysema, chronic bronchitis, asthma, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia and cystic fibrosis, with the use of aerosols, mists or sprays of the nanocrystalline antimicrobial metals.
- the invention also provides treatment for other disorders of mucosal membranes, including without limitation, prostatitis, sinusitis, digestive disorders, TENS (toxic epidermal necrolysis syndrome), Stevens Johnstone Syndrome, cystic fibrosis, bronchitis, pneumonia, pharyngitis, common cold, ear infection, sore throat, STD's (sexually transmitted diseases such as syphilis, gonorrhea, herpes, genital warts, HIV, and chlamydia), inflammatory bowel disease, colitis, hemorrhoids, thrush, dental, oral and periodontal disease such as gingivitis, dental caries, periodental inflammation and malodour.
- TENS toxic epidermal necrolysis syndrome
- Stevens Johnstone Syndrome cystic fibrosis
- bronchitis pneumonia
- pharyngitis common cold, ear infection, sore throat
- STD's sexually transmitted diseases such as syphilis, gonorr
- Methods and formulations of this invention have application to both humans and animals.
- One particularly preferred embodiment of the invention involves the treatment of respiratory disorders by the administration of the antimicrobial or noble metal as an aerosol, mist or spray, which can be generated by a nebulizer, or by delivering powders or solutions of the metal by inhalers.
- Another particularly preferred embodiment is the administration of the antimicrobial or noble metal as an instillation for such disorders as inflammatory bowel disease.
- the antimicrobial or noble metal may be administered alone, or with a carrier such as saline solutions, DMSO, an alcohol or water, most preferably water.
- An effective daily amount of the antimicrobial or noble metal will vary with the subject, but will be less than is toxic while still providing a therapeutic effect.
- An exemplary dose is from about 10 ⁇ g/kg to about 50 mg kg of body weight, more preferably 0.5 - 10 mg kg.
- antimicrobial metals preferably selected from one or more of silver, gold, platinum and palladium
- These antimicrobial metals are formed with atomic disorder, such that ions, clusters, atoms or molecules of the metals are released at a concentration sufficient to provide a localized antimicrobial and anti-inflammatory effect.
- the antimicrobial or noble metals are in a nanocrystalline form, and include sufficient atomic disorder to provide an antimicrobial and anti-inflammatory effect on a sustainable basis.
- crystalline forms of these antimicrobial or noble metals may be used in, or formulated from, any of the following formats:
- Coatings of the antimicrobial metals on medical grade substrates for example, dressings, packings, meshes, films, filtering surfaces, filters, infusers, fibres such as dental floss or sutures, containers or vials, from materials composed of, for example, polyethylene, high density polyethylene, polyvinylchloride, latex, silicone, cotton, rayon, polyester, nylon, cellulose, acetate, carboxymethylcellulose, alginate, chitin, chitosan and hydrofibres;
- Powders preferably prepared as powders of the antimicrobial or noble metals (i.e., as free standing powders), or as coatings of the antimicrobial or noble metals on biocompatible substrates in powder form, preferably on hydrocolloids, bioabsorbable and/or hygroscopic substrates such as:
- Synthetic Bioabsorbable Polymers for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers, or
- Proteins albumin, fibrin, collagen, elastin;
- Polysaccharides chitosan, alginates, hyaluronic acid;
- Occlusions or hydrated dressings in which the dressing is impregnated with a powder or solution of the antimicrobial metals, or is used with a topical formulation of the antimicrobial metals, with such dressings for example as hydrocolloids, hydrogels, polyethylene, polyurethane, polvinylidine, siloxane or silicone dressings
- Gels formulated with powders or solutions of the antimicrobial or noble metals with such materials as hydrocolloid powders such as carboxymethylcellulose, alginate, chitin, chitosan and hydrofibres, together with such ingredients as preservatives, pectin and viscosity enhancers;
- Formulations suitable for administration to the nasal membranes, the oral cavity or to the gastrointestinal tract formulated with powders or liquids of the antimicrobial or noble metal in such forms as lozenges, toothpastes, gels, powders, coated dental implants, dental floss or tape, chewing gum, wafers, mouth washes or rinses, drops, sprays, elixirs, syrups, tablets, or capsules;
- Formulations suitable for vaginal or rectal administration formulated with powders or liquids of the antimicrobial or noble metal in such forms as suppositories, dressings, packings, tampons, creams, gels, ointments, pastes, foams, sprays, and solutions for retention enemas or instillations.
- Solutions of the antimicrobial or noble metals may lose some activity with aging and are thus either stabilized or generated fresh for administration.
- the antimicrobial or noble metals may be packaged for convenient solution generation, for instance in a pervious membrane such as a tea bag-type infusers.
- Other two part systems or two phase may be used in which the metal coating or powder is separated from any liquid carrier or hydrating agents, for example packaging the components in kit form, with the antimicrobial metal being provided in dissolving capsules, as a coating on the inside of vials or containers, on substrates such as dressings, separated by a membrane which can be perforated, or in a separate container from the carrier etc.
- the antimicrobial or noble metals are thus formulated from coatings or powders of the antimicrobial or noble metals, or from solutions prepared by dissolving the coatings or powders therein.
- the formulations include a therapeutically effective amount of the coatings or powders, and most preferably, the following amounts:
- coatings 150 - 3000 nm thick coatings for substrates, or thicker for forming powders (such coatings can be used to generate 0.001 to 10% by weight solutions)
- Concentrations of the antimicrobial or noble metal species in solution will vary according to the application, formulation and subject, but will generally range from 1 - 5000 ig/ml, more preferably 20 - 3000 g/ml, more preferably 40 - 800 ⁇ g/ml, and most preferably 50 - 500 ⁇ g/ml.
- Nanocrystalline coatings of the antimicrobial or noble metals are most preferably deposited onto substrates such as dressings, for example one or more layers of medical dressing materials which can be laminated with uncoated layers of medical dressing materials.
- the coatings can be prepared by known techniques for preparing nanocrystalline coatings, but are most preferably prepared by physical vapour deposition under conditions which create atomic disorder.
- the nanocrystalline coatings may be prepared to create an interference colour so as to provide an indicator, as described in prior patent application WO 98/41095, published September 24, 1998, and naming inventors R. E. Burrell and R. J. Precht.
- Nanocrystalline powders of the antimicrobial or noble metals may be prepared as nanocrystalline coatings preferably of the above thickness, on powdered substrates such as chitin, or may be prepared as nanocrystalline coatings on a substrate such as a silicon wafer, and then scraped off as a nanocrystalline powder.
- fine grained or nanocrystalline powders of the antimicrobial or noble metals may be cold worked to impart atomic disorder, as disclosed in prior patent application WO 93/23092, published November 25, 1993, naming Burrell et al, as inventors.
- the invention broadly provides a method of reducing inflammation or infection of a mucosal membrane, comprising contacting a problem area of the mucosal membrane with a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide a localized anti-inflammatory effect, wherein the one or more antimicrobial metals are characterized by sufficient atomic disorder, such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized anti-inflammatory effect.
- a method of reducing inflammation or infection of a mucosal membrane comprising: a) providing a therapeutically effective amount of one or more antimicrobial metals in a crystalline form characterized by sufficient atomic disorder such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized anti- inflammatory effect.
- the invention provides a kit for reducing inflammation or infection of a mucosal membrane comprising a therapeutically effective amount of one or more antimicrobial metals in a crystalline form characterized by sufficient atomic disorder such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal, the one or more antimicrobial metals being provided in a dosage form to provide a localized anti-inflammatory effect to the mucosal membrane.
- Metal or “metals” includes one or more metals whether in the form of substantially pure metals, alloys or compounds such as oxides, nitrides, borides, sulphides, halides or hydrides.
- Antimicrobial metals are silver, gold, platinum, palladium, iridium, zinc, copper, tin, antimony, bismuth, or mixtures of these metals with same or other metals, silver, gold, platinum and palladium being preferred, and silver being most preferred.
- Noble metals are silver, gold, platinum and palladium, or mixtures of such metals with same or other metals, with silver metal being the most preferred.
- Antimicrobial effect means that atoms, ions, molecules or clusters of the antimicrobial or noble metal are released into the electrolyte which the coating contacts in concentration sufficient to inhibit microbial growth on and in the vicinity of the coating.
- the most common methods of measuring an antimicrobial effect are a zone of inhibition test (which indicates an inhibitory effect, whether microbiostatic or microbiocidal) or a logarithmic reduction test (which indicates a microbiocidal effect).
- ZOI zone of inhibition test
- the material to be tested is placed on a bacterial lawn (or a lawn of other microbial species) and incubated. A relatively small or no ZOI (ex.
- a logarithmic reduction test in viable bacteria is a quantitative measure of the efficacy of an antibacterial treatment; for example, a 5 log reduction means a reduction in the number of microorganisms by 100,000-fold (e.g., if a product contained 100,000 pertinent microorganisms, a 5 log reduction would reduce the number of pertinent microorganisms to 1). Generally, a 3 log reduction represents a bactericidal effect.
- the logarithmic reduction test involves combining an inoculum of bacteria or other microbial species with the test treatment, incubating the inoculum with the test treatment, recovering the bacteria or other microbial species, and enumerating the bacteria or other microbial species using serial dilutions. Examples of these tests are set out in the examples which follow.
- Anti-inflammatory effect means a reduction in one ore more of the symptoms of erythema (redness), edema (swelling), pain and pruritus which are characteristic of inflammatory conditions of mucosal membranes.
- Biocompatible means generating no significant undesirable host response for the intended utility. Most preferably, biocompatible materials are non-toxic for the intended utility. Thus, for human utility, biocompatible is most preferably non-toxic to humans or human tissues.
- “Sustained release” or “sustainable basis” are used to define release of atoms, molecules, ions or clusters of an antimicrobial metal that continues over time measured in hours or days, and thus distinguishes release of such metal species from the bulk metal, which release such species at a rate and concentration which is too low to be therapeutically effective, and from highly soluble salts of antimicrobial metals such as silver nitrate, which releases silver ions virtually instantly, but not continuously, in contact with an alcohol or electrolyte.
- “Atomic disorder” includes high concentrations of one or more of: point defects in a crystal lattice, vacancies, line defects such as dislocations, interstitial atoms, amorphous regions, grain and sub grain boundaries and the like relative to its normal ordered crystalline state. Atomic disorder leads to irregularities in surface topography and inhomogeneities in the structure on a nanometer scale.
- Normal ordered crystalline state means the crystallinity normally found in bulk metal materials, alloys or compounds formed as cast, wrought or plated metal products. Such materials contain only low concentrations of such atomic defects as vacancies, grain boundaries and dislocations.
- “Diffusion”, when used to describe conditions which limit diffusion in processes to create and retain atomic disorder, i.e. which freeze-in atomic disorder, means diffusion of atoms (adatom diffusion) and/or molecules on the surface or in the matrix of the material being formed.
- Alcohol or water-based electrolyte is meant to include any alcohol or water-based electrolyte that the antimicrobial materials of the present invention might contact in order to activate (i.e. cause the release of species of the antimicrobial metal) into same.
- the term is meant to include alcohols (short chain (C 6 or less) and preferably C 4 or less), water, gels, fluids, solvents, and tissues containing, secreting or exuding water or water-based electrolytes, including body fluids (for example blood, urine or saliva), and body tissue (for example mucosal membranes).
- Bioabsorbable as used herein in association includes substrates which are useful in medical devices, that is which are biocompatible, and which are capable of bioabsorption in period of time ranging from hours to years, depending on the particular application.
- Bioabsorption means the disappearance of materials from their initial application site in the body (human or mammalian) with or without degradation of the dispersed polymer molecules.
- Cold change is meant to include changes of intensity of light under monochromatic light as well as changes of hue from white light containing more than one wavelength.
- An “interference colour” is produced when light impinges on two or more partly reflective surfaces separated by a distance which bears the right relationship to the wavelength of the light to be removed by destructive interference.
- Partly reflective when used to describe the base or top layer materials, means that the material has a surface which reflects a portion of incident light, but which also transmits a portion of the incident light. Reflection occurs when a ray of incoming light encounters a boundary or interface characterized by a change in refractive index between two media.
- That interface is with air.
- the interface is with the top layer. The reflectance of the base and top layers is balanced so as to generate an interference colour.
- Partly light transmissive when used to describe a thin film of the top layer material means that the thin film is capable of transmitting at least a portion of incident visible light through the thin film.
- Detectable when used to describe a colour change means an observable shift in the dominant wavelength of the reflected light, whether the change is detected by instrument, such as a spectrophotometer, or by the human eye.
- the dominant wavelength is the wavelength responsible for the colour being observed.
- Cold working indicates that the material has been mechanically worked such as by milling, grinding, hammering, mortar and pestle or compressing, at temperatures lower than the recrystallization temperature of the material. This ensures that atomic disorder imparted through working is retained in the material.
- “Pharmaceutically- or therapeutically-acceptable” is used herein to denote a substance which does not significantly interfere with the effectiveness or the biological activity of the active ingredients (antimicrobial and anti-inflammatory activities) and which is not toxic or has an acceptable toxic profile to the host to which it is administered.
- “Therapeutically effective amount” is used herein to denote any amount of a formulation of the antimicrobial or noble metals which will exhibit either or both of an antimicrobial and optionally an anti-inflammatory effect, when applied to the affected area of the mucosal membrane.
- a single application of the formulations of the present invention may be sufficient, or the formulations may be applied repeatedly over a period of time, such as several times a day for a period of days or weeks.
- the amount of the active ingredient, that is the antimicrobial or noble metal in the form of a coating, powder or dissolved in liquid solution will vary with the conditions being treated, the stage of advancement of the condition, the age and type of host, and the type and concentration of the formulation being applied. Appropriate amounts in any given instance will be readily apparent to those skilled in the art or capable of determination by routine experimentation.
- Carrier means a suitable vehicle including one or more solid, semisolid or liquid diluents, excipients or encapsulating substances which are suitable for administration to the mucosal membrane.
- Nanocrystalline is used herein to denote single-phase or multi-phase polycrystals, the grain size of which is less than about 100, more preferably ⁇ 50, even more preferably ⁇ 40, even more preferably ⁇ 30, and most preferably ⁇ 25 nanometers in at least one dimension.
- the term, as applied to the crystallite or grain size in the crystal lattice of coatings, powders or flakes of the antimicrobial or noble metals, is not meant to restrict the particle size of the materials when used in a powder form.
- Powder is used herein to include particulates of the antimicrobial or noble metals ranging from nanocrystalline (less than 100 nm) to submicron sized powders up to flakes.
- powders of the antimicrobial or noble metals used in the present invention are sized at less than 100 ⁇ m, and more preferably less than 40 ⁇ m, and most preferably less than 10 ⁇ m.
- Gram size or “crystallite size” means the size of the largest dimension of the crystals in the antimicrobial metal coating or powder.
- Hydrocolloid means a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent).
- the swelling agent must be capable of swelling the hydrocolloid chosen in order to form the gel phase.
- Hydrocolloid means a hydrocolloid swollen with water or another hydrophilic liquid which is used for absorbing or retaining moisture or water.
- Gel means a composition that is of suitable viscosity for such purposes, e.g., a composition that is of a viscosity that enables it to be applied and remain on a substrate or the mucosal membrane.
- Mucosal membrane includes the epithelial membranes which line the oral cavity, the nasal, bronchial, pulmonary, trachea and pharynx airways, the otic and ophthalmic surfaces, the urogenital system, including the prostate, the reproductive system and the gastrointestinal tract, including the colon and rectal surfaces.
- Reference to mucosal membrane herein is meant to include the surface membranes or cell structures of the mucosal membrane at a targeted site.
- Diseases or conditions of the oral cavity means diseases or conditions of the oral cavity whether infectious, inflammatory or immunologic in origin, including without limitation periodontal disease, gingivitis, periodontitis, periodontosis, inflammatory conditions of the tissues within the oral cavity, caries, necrotizing ulcerative gingivitis, oral or breath malodor, herpetic lesions, infections following dental procedures such as osseous surgery, tooth extraction, periodontal flap surgery, dental implantation, scaling and root planing, dentoalveolar infections, dental abscesses (e.g., cellulitis of the jaw; osteomyelitis of the jaw), acute necrotizing ulcerative gingivitis, infectious stomatitis (i.e., acute inflammation of the buccal mucosa), Noma (i.e., gangrenous stomatitis or cancrum oris), sore throat, pharyngitis, and thrush.
- gingivitis gingivitis, periodontitis, periodontosis
- Respiratory disorders means respiratory disorders of the nasal, bronchial, pulmonary, trachea and pharynx airways whether infectious, inflammatory or immunologic in origin, including without limitation emphysema, chronic bronchitis, asthma, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia, TENS, Stevens Johnstone Syndrome, common cold, sore throat, pharyngitis, and cystic fibrosis.
- Gastrointestinal disorders means disorders of the gastrointestinal tract whether infectious, inflammatory or immunologic in origin, including without limitation, digestive ulcers such as esophageal ulcer, gastric ulcer and duodenal ulcer, and also esophagitis, gastritis, enteritis, enterogastric intestinal hemorrhage, colitis, inflammatory bowel disease, and hemorrhoids.
- nasal disorders means disorders of the nasal passages whether infectious, inflammatory or immunologic in origin, including without limitation sinusitis.
- disorders of the urogenital and reproductive systems means disorders of these systems whether infectious, inflammatory or immunologic in origin, including without limitation STD's, HIV, chlamydia, syphilis, gonorrhea, Herpes, genital warts, and prostatitis.
- nanocrystalline antimicrobial metal and similar terminology such as “nanocrystalline coating or powder” is meant to refer to antimicrobial metal, coating or powder formed with atomic disorder and having a nanocrystalline grain size.
- Crystalline forms of the antimicrobial metal or noble metals can be prepared as coatings or powders, or as liquids prepared by dissolving the coatings or powders.
- the crystalline coatings or powders are most preferably formed with atomic disorder in accordance with the techniques published in the prior patent applications of Burrell et al, see for example WO 93/23092, published November 25, 1993, WO 95/13704, published May 26, 1995 and WO 98/41095, published September 24, 1998.
- compositions for treatment of mucosal membranes utilize the antimicrobial or noble metals in powder, coatings or solution form.
- Preparation of the antimicrobial or noble metals as powders or coatings is set out below in section A, format for formulations are set forth in section B, sterilization in section C, and formulating, dosages and treatment are set forth in section D.
- Dressings or other substrates such as packings, vials, fabric, fibres, liners, mesh, filtering surfaces etc. may be coated with antimicrobial coatings formed with atomic disorder.
- the description below is directed to coatings on dressing materials, but the coating techniques are equally applicable to coating other substrates.
- Dressings coated with antimicrobial metals in accordance with the invention include one or more layers of medical dressing materials. Multiple layers may be laminated together by known means such as low temperature thermal fusing, stitching or, most preferably, ultrasonic welding.
- the dressing may be formed to include an occlusive or semi-occlusive layer such as an adhesive tape or polyurethane film in order to secure the dressing in place, and retain moisture for release of ions, atoms, molecules or clusters of the antimicrobial metal (hereinafter antimicrobial metal species).
- an occlusive or semi-occlusive layer such as an adhesive tape or polyurethane film in order to secure the dressing in place, and retain moisture for release of ions, atoms, molecules or clusters of the antimicrobial metal (hereinafter antimicrobial metal species).
- the dressing is formed of a perforated, preferably non-adherent material which allows for fluids to penetrate or diffuse there through in either or both directions.
- the perforated material may be formed of a woven or non-woven, non-woven being preferred, fabric such as cotton, gauze, a polymeric net or mesh such as polyethylene, nylon, polypropylene or polyester, an elastomer such as polyurethane or polybutadiene elastomers, or a foam such as open cell polyurethane foam.
- Exemplary perforated, non-adherent materials useful for the dressing include non-woven meshes such as DELNETTM P530, which is a non-woven veil formed of high density polyethylene using extrusion, embossing and orientation processes, produced by Applied Extrusion Technologies, Inc. Of Middletown, Delaware, USA. This same product is available as Exu-Dry CONFORMANT 2TM Wound Veil, from Frass Survival Systems, Inc., Bronx, New York, USA as a subset of that company's Wound Dressing Roll (Non- Adherent) products.
- DELNETTM P530 is a non-woven veil formed of high density polyethylene using extrusion, embossing and orientation processes, produced by Applied Extrusion Technologies, Inc. Of Middletown, Delaware, USA.
- This same product is available as Exu-Dry CONFORMANT 2TM Wound Veil, from Frass Survival Systems, Inc., Bronx, New York, USA as a subset of that company's Wound Dress
- non-woven meshes include CARELLETM or NYLON 90TM, available from Carolina Formed Fabrics Corp., N-TERFACETM, available from Winfield Laboratories, Inc., of Richardson, Texas, USA.
- Exemplary woven meshes may be formed from fibreglass or acetate, or cotton gauze.
- An exemplary hydrophilic polyurethane foam is HYPOLTM, available from W.R. Grace & Co., New York, NY, USA.
- At least one dressing layer is preferably formed from a polymeric material which is amenable to ultrasonic welding, that is which will melt on the application of localized heat and then fuse multiple layers together on cooling.
- a second, absorbent layer is formed from an absorbent material for holding sufficient moisture next to the mucosal membrane in order to activate the antimicrobial metal coating, that is to cause release of ions, molecules, atoms or clusters of the antimicrobial metal in order to cause an antimicrobial and anti-inflammatory effect.
- the absorbent material is an absorbent needle punched non-woven rayon/polyester core such as SONTARATM 8411, a 70/30 rayon/polyester blend commercially available from Dupont Canada, Mississauga, Ontario, Canada. This product is sold by National Patent Medical as an American White Cross sterile gauze pad.
- absorbent materials include woven or non-woven materials, non- woven being preferred made from fibers such as rayon, polyester, rayon/polyester, polyester/cotton, cotton and cellulosic fibers.
- woven or non-woven materials being preferred made from fibers such as rayon, polyester, rayon/polyester, polyester/cotton, cotton and cellulosic fibers.
- Exemplary are creped cellulose wadding, an air felt of air laid pulp fibers, cotton, gauze, and other well known absorbent materials suitable for medical dressings.
- a third layer of the dressing is preferably formed of perforated, non-adherent material such as used in the first layer. This allows moisture penetration as sterile water and the like are added in order to activate the antimicrobial metal coating. Additional layers may be included between or above the first, second and third layers as is well known in medical dressings.
- the coated dressing layers may be combined with an adhesive layer, in a well known manner.
- the dressing may be used as a single layer, or may be used as multiple layers laminated together at intermittent spaced locations across the dressing by ultrasonic welds.
- Ultrasonic welding is a known technique in the quilting art. Briefly, heat (generated ultrasonically) and pressure are applied to either side of the dressing at localized spots through an ultrasonic horn so as to cause flowing of at least one of the plastic materials in the first and second layers and the subsequent bonding together of the layers on cooling.
- the welds appear at localized circular spots and are preferably less than 0.5 cm in diameter.
- the use of ultrasonic welding of the layers at spaced locations has the advantage of retaining the absorbent and moisture penetration properties of the dressing layers, while retaining the conforming properties of the dressing. Edge seams, stitching and adhesives have the disadvantage of interfering with one or more of these desirable properties of the dressings.
- the dressing may be cut to smaller sizes, as needed, without causing delamination. Preferred spacings of about 2.5 cm between welds allows the dressing to be cut down to about 2.5 cm sizes, while maintaining at least one weld to hold the laminated layers together, ii) Nanocrystalline Coatings of Antimicrobial Metals
- the coated substrate for example a dressing, preferably includes a nanocrystalline coating of one or more of the antimicrobial metals.
- the coating is applied to one or more of the dressing layers, but is most preferably applied at least to the mucosal membrane facing layer.
- the nanocrystalline coating is most preferably formed with atomic disorder in accordance with the procedures set out above and as described in WO 93/23092, WO 95/13704, and WO98/41095, and as set out below.
- the coating is formed as a multilayer coating of the antimicrobial metals, having a top and a base layer, as set below, to produce an interference colour. In this way, the coating provides not only the active ingredient for the treatment of mucosal membranes, but also acts as an indicator of activation of the dressing.
- the top layer of the coating is activated with an alcohol or water-based electrolyte, such as sterile water or ethanol, even minor dissolution of the antimicrobial metal results in a detectable colour change, indicating that the coating has been activated. If there is no colour change, additional moisture might be provided to the dressing by adding water, until a colour change is detected. Once activated, the dressing should be maintained in a moist condition, for example by the addition of sterile water, if necessary, iii) Multilayer Nanocrystalline Coatings of Antimicrobial Metals With Interference Colour
- the coated substrates for example dressings may include the antimicrobial metal coating formed with at least two metal layers, a base layer and a top layer over the base layer, so as to produce an interference colour, as set forth in WO 98/41095, the teachings of which are incorporated herewith by reference.
- the indicator colour can function as an indicator when contacted with a water or alcohol-based electrolyte, since the coating will change colour.
- An exemplary multilayer nanocrystalline coating of silver with a blue interference colour is set forth in Example 1.
- the coatings of the present invention are formed in a crystalline form from one or more antimicrobial metals with atomic disorder.
- the production of atomic disorder through physical vapour deposition techniques is described in WO 93/23092 and WO 95/13704, and as outlined below.
- the antimicrobial metal is deposited as a thin metallic film on one or more surfaces of the dressing by vapour deposition techniques.
- Physical vapour techniques which are well known in the art, all deposit the metal from the vapour, generally atom by atom, onto a substrate surface.
- the techniques include vacuum or arc evaporation, sputtering, magnetron sputtering and ion plating.
- the deposition is conducted in a manner to create atomic disorder in the coating as defined above.
- Various conditions responsible for producing atomic disorder are useful. These conditions are generally those which one has been taught to avoid in thin film deposition techniques, since the object of most thin film depositions is to create a defect free, smooth and dense film (see for example J.A. Thornton, "Influence of Apparatus Geometry and Deposition Conditions on the Structure and Topography of Thick Sputtered Coatings," J. Vac. Sci. Technol., 11(4), 666-670, 1974).
- the preferred conditions which are used to create atomic disorder during the deposition process include:
- a low substrate temperature that is maintaining the surface to be coated at a temperature such that the ratio of the substrate temperature to the melting point of the metal (in degrees Kelvin) is less than about 0.5, more preferably less than about 0.35 and most preferably less than about 0.3; and optionally one or both of:
- a higher than normal working gas pressure i.e. for vacuum evaporation: e-beam or arc evaporation, greater than 0.001 Pa (0.01 mT), gas scattering evaporation (pressure plating) or reactive arc evaporation, greater than 2.67 Pa (20 mT); for sputtering: greater than 10 Pa (75 mT); for magnetron sputtering: greater than about 1.33 Pa (10 mT); and for ion plating: greater than about 26.67 Pa (200 mT); and
- the thin metal film has a thickness no greater than that needed to provide release of antimicrobial metal species on a sustainable basis over a suitable period of time, and to generate the desired interference colour.
- the thickness will vary with the particular metal in the coating (which varies the solubility and abrasion resistance), and with the degree of atomic disorder in (and thus the solubility of) the coating. The thickness will be thin enough that the coating r does not interfere with the dimensional tolerances or flexibility of the device for its intended utility.
- the therapeutic effect of the material so produced is achieved when the coating is brought into contact with an alcohol or a water-based electrolyte, thus releasing metal ions, atoms, molecules or clusters.
- concentration of the metal species which is needed to produce a therapeutic effect will vary from metal to metal.
- the ability to achieve release of metal atoms, ions, molecules or clusters on a sustainable basis from a coating is dictated by a number of factors, including coating characteristics such as composition, structure, solubility and thickness, and the nature of the environment in which the device is used. As the level of atomic disorder is increased, the amount of metal species released per unit time increases. For instance, a silver metal film deposited by magnetron sputtering at T/Tm ⁇ 0.5 and a working gas pressure of about 0.93 Pa (7 mT) releases approximately 1/3 of the silver ions that a film deposited under similar conditions, but at 4 Pa (30 mT), will release over 10 days. Films that are created with an intermediate structure (ex.
- the time required for total dissolution will be a function of film thickness and the nature of the environment to which they are exposed.
- the relationship in respect of thickness is approximately linear, i.e. a two fold increase in film thickness will result in about a two fold increase in longevity.
- a coating deposited by magnetron sputtering such that the working gas pressure was low (ex. 2 Pa or 15 mT) for 50% of the deposition time and high (ex. 4 Pa or 30 mTorr) for the remaining time, has a rapid initial release of metal ions, followed by a longer period of slow release.
- This type of coating is extremely effective on devices such as urinary catheters for which an initial rapid release is required to achieve immediate antimicrobial concentrations followed by a lower release rate to sustain the concentration of metal ions over a period of weeks.
- the substrate temperature used during vapour deposition should not be so low that annealing or recrystallization of the coating takes place as the coating warms to ambient temperatures or the temperatures at which it is to be used (ex. body temperature).
- This allowable ⁇ T that the temperature differential between the substrate temperature during deposition and the ultimate temperature of use, will vary from metal to metal.
- metal For the most preferred metal, Ag, preferred substrate temperatures of -20 to 200°C , more preferably -10°C to 100°C are used.
- Atomic order may also be achieved, in either or both of the base and top layers by preparing composite metal materials, that is materials which contain one or more antimicrobial metals in a metal matrix which includes atoms or molecules different from the antimicrobial metals.
- the preferred technique for preparing a composite material is to co- or sequentially deposit the antimicrobial metal(s) with one or more other inert, biocompatible metals selected from Ta, Ti, Nb, Zn, V, Hf , Mo, Si, Al and alloys of these metals or other metal elements, typically other transition metals.
- inert metals have a different atomic radii from that of the antimicrobial metals, which results in atomic disorder during deposition. Alloys of this kind can also serve to reduce atomic diffusion and thus stabilize the disordered structure.
- Thin film deposition equipment with multiple targets for the placement of each of the antimicrobial and biocompatible metals is preferably utilized.
- the layer(s) of the biocompatible metal(s) should be discontinuous, for example as islands within the antimicrobial metal matrix.
- the final weight ratio of the antimicrobial metal(s) to biocompatible metal(s) should be greater than about 0.2.
- the most preferable biocompatible metals are Ti, Ta, Zn and Nb. It is also possible to form the antimicrobial coating from oxides, carbides, nitrides, sulphides, borides, halides or hydrides of one or more of the antimicrobial metals and/or one or more of the biocompatible metals to achieve the desired atomic disorder.
- Another composite material may be formed by reactively co- or sequentially depositing, by physical vapour techniques, a reacted material into the thin film of the antimicrobial metal(s).
- the reacted material is an oxide, nitride, carbide, boride, sulphide, hydride or halide of the antimicrobial and/or biocompatible metal, formed in situ by injecting the appropriate reactants, or gases containing same, (ex. air, oxygen, water, nitrogen, hydrogen, boron, sulphur, halogens) into the deposition chamber. Atoms or molecules of these gases may also become absorbed or trapped in the metal film to create atomic disorder.
- the reactant may be continuously supplied during deposition for codeposition or it may be pulsed to provide for sequential deposition.
- the final weight ratio of reaction product to antimicrobial metal(s) should be greater than about 0.05. Air, oxygen, nitrogen and hydrogen are particularly preferred reactants, with oxygen being most preferred.
- the above deposition techniques to prepare composite coatings may be used with or without the conditions of lower substrate temperatures, high working gas pressures and low angles of incidence previously discussed. One or more of these conditions are preferred to retain and enhance the amount of atomic disorder created in the coating.
- the most preferred composite coatings are formed by sputtering silver, under conditions set out above, in an atmosphere containing oxygen, so as to form a coating of silver as a composite coating with oxygen.
- Dressings coated with the antimicrobial coatings of this invention may be sterilized in the manner set out below, b) Powders of Atomically Disordered Antimicrobial Metals
- Crystalline powder forms of the antimicrobial or noble metals can be prepared as free standing powders, by coating powdered substrates, or from coatings on substrates which are then collected, for example by scraping, and then sized.
- the powders may be prepared as pure metals, metal alloys or compounds such as metal oxides or metal salts, by vapour deposition, mechanical working, or compressing to impart the atomic disorder.
- the crystalline powders are formed with atomic disorder in accordance with the techniques set out above and as published in the prior patent applications of Burrell et al, see for example WO 93/23092, published November 25, 1993, and WO 95/13704, published May 26, 1995.
- the atomic disorder will most typically be formed in the metal powders during physical vapour deposition as set out above for coatings or by mechanically imparting the disorder, such as by milling, grinding, hammering, mortar and pestle or compressing, under conditions of low temperature (i.e., temperatures less than the temperature of recrystallization of the material) to ensure that annealing or recrystallization does not take place.
- the powders may be formed by inert-gas condensation techniques, which are modified to provide atomic disorder in the powder produced, as taught in WO 95/13704 to Burrell et al.
- Powders of the antimicrobial or noble metals are preferably formed by physical vapour deposition (PVD) onto a substrate such as a cold finger, a silicon wafer, solid plates, a rotating cylinder, a continuous belt in a roll coater, or on steel collectors in known PVD coaters.
- PVD physical vapour deposition
- Preparation of powders of the present invention by sputtering onto a continuous belt in a roll coater, or other some other moving or rotating substrate surface is particularly advantageous, inasmuch as it can quickly and easily yield a relatively large supply of freestanding powder at a relatively low cost.
- a stainless steel belt can be used in the roll coating process without the need to provide additional cooling of the substrate.
- the powders or coatings and then are then scraped off to form a powder, and may be sized to avoid overly large particulates.
- the powders are scraped off the moving surface with scrapers which contact the moving surface at an angle sufficient to remove the coating in flake or powder form.
- the coating may be scraped off with scrapers angled for forward cutting of the coating from the moving surface, or with scrapers which remove the coating from the moving surface by reverse dragging action on the surface.
- the scrapers may be suspended above the belt, and either weighted or spring loaded to apply pressure sufficient to remove the coating from the moving surface. With a continuous belt, the scrapers can conveniently be located above the end rollers to remove the coating with a reverse dragging action as the belt rounds the end roller.
- the powders of the antimicrobial or noble metals may be formed on powdered substrates which are biocompatible, or otherwise compatible for the end use of the powder.
- powdered substrates are hydrocolloids, particularly those which are bioabsorbable and/or hygroscopic powders such as chitin.
- Exemplary bioabsorbable and/or hygroscopic powders are composed of :
- Synthetic Bioabsorbable Polymers for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., poly anhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers.
- Naturally Derived Polymers Proteins: albumin, fibrin, collagen, elastin; Polysaccharides: chitosan, alginates, hyaluronic acid; and Biosynthetic Polyesters: 3-hydroxybutyrate polymers.
- the powders may be incorporated into or onto medical dressings or pharmaceutical formulations, by any methods known in the art.
- the powders may be layered onto the substrates (dressings or powders), mechanically fixed within the fibres of the dressings, impregnated into dressings by physical blowing, or added to topical pharmaceutical ingredients.
- powders of the present invention are sized at less than 100 ⁇ m, and more preferably less than 40 ⁇ m, and most preferably about 3 - 5 ⁇ m in size.
- powders are preferably sized less than 2 ⁇ m, and more preferably less than 1 ⁇ m.
- Coated Substrates coated with antimicrobial metals formed with atomic disorder are described above. These techniques can be used to coat dressings, meshes, films, filtering surfaces, filters, packings, fibres such as dental floss and sutures, the inside of vials or containers etc.
- the coated substrates in the form of dressings or packings etc. can be used directly on the affected area of the mucosal membrane, or they can be used to generate powders, liquid or other formulations as set out below.
- Powders of the antimicrobial metals formed with atomic disorder are set out above, and may be used in that form directly on the affected area of the mucosal membrane, or in other formulations such as dressings, occlusions, creams, liquids etc.
- powders may be formulated within liquid pervious membranes such as filters, meshes and the like, such as a tea bag-type infuser, for generating liquids containing dissolved species of the antimicrobial metal.
- Occlusions may include a hydrated dressing, with a sealing material overlaid on the outside, to the area of mucosal membrane to be treated.
- the term hydrated dressing is meant to include non-hydrated dressings which become hydrated upon contact with an alcohol or water-based electrolyte. Occlusion prevents loss of the therapeutic agent from the mucosal membrane, promotes hydration, and increases mucosal membrane temperature.
- Examples of hydrated dressings include hydrocolloids, hydrogels, polyethylene, polyurethane, polyvinylidine, and siloxane or silicone dressings.
- the hydrated dressing can either be impregnated with a solution or powder of the antimicrobial metals of this invention, or can be used with a topical formulation of the antimicrobial metals of this invention.
- An exemplary occlusion is a hydrocolloid dressing impregnated with nanocrystalline silver.
- a non-impregnated hydrocolloid dressing to occlude a nanocrystalline silver-containing gel placed on a problematic area of the mucosal membrane.
- a hydrocolloid is a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent).
- the swelling agent is a hydrophilic liquid capable of swelling the hydrocolloid chosen in order to form the gel phase.
- the hydrocolloid may be selected from the group comprising: a) representative natural or synthetically modified polysaccharides (e.g., cellulose or its derivatives such as carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose, starch, glycogen, gelatin, pectin, chitosan and chitin; and b) representative gums from algal extracts, seed extracts, or plant exudates (e.g., gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, alginates, carob gum, guar gum, xanthan gum); and c) synthetic polymers which may be either linear or crosslinked (e.g. polymers prepared from N-vinyl lactams, e.g. N-vinyl-2-pyrrolidone, 5-methyl-N-vinyl-2-pyrrolidon
- the hydrocolloid is present in an amount of from about 0.1% to 20% of the weight and preferably 1% to 10%.
- the hydrocolloid can range for example, from 1 to 10% of the total weight of the composition.
- the hydrocolloid may be in the form of a powder whose average particle size is less than 100 ⁇ m, and preferably less than 50 ⁇ m.
- non-volatile swelling agents include room temperature liquid polyols (including polyhydric alcohols) such as glycerol; room temperature solid polyols (including polyhydric alcohols) such as sorbitol, erythritol, threitol, ribotol, arabinitol, xylitol, allitol, talitol, mannitol, glucitol, glactitol, iditol, pentaerythritol, heptitol, octitol, nonitol, decitol, and dodecitol, blended with a room temperature liquid polyol; monoanhydroalditols (such as styracitol, polyalitol, D-fructose, 1,4
- Hydrocolloid dressings often comprise a wafer constructed from a thin layer of polyurethane film with an adhesive contact layer containing a hydrocolloid composition and securing the dressing to the mucosal membrane, and the polyurethane film being impermeable to water and microorganisms.
- Hydrocolloid dressings may be prepared by dispersing a composition in gel form of hydrocolloids with a swelling agent into a strong pressure sensitive adhesive. Alternatively, the gel and the adhesive may be mixed in a latex solution.
- exemplary products are available commercially, for example DuoDERMTM (ConvaTec Canada, 555, Dr.
- the hydrocolloid dressing may be impregnated with a solution or powder of the antimicrobial metals by blending the solution or powder of the antimicrobial metal into a liquid phase during the manufacture of the hydrocolloid dressing, or by sprinkling and then pressing a powder of the antimicrobial metal into the surface of the hydrocolloid dressing. Further, the hydrocolloid dressing can be used with a topical formulation of the antimicrobial metals of this invention . Upon application, the dressing surface gels upon continued contact with moisture, secretions or exudate from the mucosal membrane.
- the dressing With the incorporation of an antimicrobial metal such as silver (0.01 - 10%, preferably 0.1 - 1% by weight), the dressing is advantageous in being impermeable to water and microorganisms, and presenting antimicrobial and anti-inflammatory effects as mediated by the antimicrobial metal.
- an antimicrobial metal such as silver (0.01 - 10%, preferably 0.1 - 1% by weight
- Gels - Nanocrystalline gels may be formed from the nanocrystalline metal powder in admixture with gelling agents such as hydrocolloids and hydrogels in powder form.
- Exemplary gelling agents include carboxymethyl cellulose (CMC), polyvinyl alcohol (PVA), collagen, pectin, gelatin, agarose, chitin, chitosan, and alginate, with the gelling agent comprising between about 0.01 - 20 % w/v.
- the antimicrobial metals may be incorporated into creams, lotions, pastes, ointments or foams formulated with nanocrystalline powders or solutions of the antimicrobial metals, for example as emulsions or with drying emollients.
- Ointments and creams can be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- bases may include water and/or an oil such as liquid paraffin or a vegetable oil such as peanut oil or castor oil.
- An exemplary base is water.
- Thickening agents which can be used according to the nature of the base include aluminum stearate, hydrogenated lanolin, and the like.
- lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, colouring agents, perfumes, and the like.
- Ointments and creams can also contain excipients, such as starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, and talc, or mixtures thereof.
- Lotions may be formulated with an aqueous or oily base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, colouring agents, perfumes, and the like.
- Foams may be formed with known foaming or surface active agents.
- Liquids - The crystalline forms of the antimicrobial metals may be incorporated into liquids, formulated as solutions, dispersions or suspensions by dissolving nanocrystalline coatings or powders of the antimicrobial metals, for example as topical solutions, aerosols, mists, sprays, drops, and instillation solutions for body cavities and tubes such as the bladder, prostate, perintheal, pericharcliar, pleural, intestinal and ailimentary canal.
- Administration of the antimicrobial metal to the mucosal membrane may be performed by aerosol, which can be generated by a nebulizer, or by instillation.
- the antimicrobial or noble metal may be administered alone, or with a carrier such as saline solution, DMSO, an alcohol or water.
- An effective daily amount of the antimicrobial or noble metal will vary with the subject, but will be less than is toxic while still providing a therapeutic effect.
- Solutions and formulations of the antimicrobial metals may lose some activity with aging and are thus either stabilized or generated fresh for administration.
- the antimicrobial metals may be packaged for convenient solution generation, for instance as tea bag-type infusers.
- Other two part or two phase systems may be used in which the nanocrystalline metal is separated from the water or alcohol-based electrolyte, for example in a multicomponent kit form, as set out herein.
- Concentrations of the antimicrobial metal species in solution will vary according to the application, formulation and subject, but will generally range from 1 - 5000 g/ml, more preferably 20 - 3000 ⁇ g/ml, more preferably 40 - 800 ⁇ g/ml, and most preferably 50 - 500 ⁇ g/ml.
- Methods of generating liquids with appropriate concentrations of the antimicrobial metal through pH control are set out below and in the examples. Control over droplet size for aerosol formulations is also addressed below.
- Transdermal Patch - Transdermal patches may provide controlled delivery of the antimicrobial metal to the mucosal membrane.
- an adhesive patch or adhesive matrix patch can be prepared from a backing material and an adhesive, such as an acrylate adhesive. Powders or solutions of the antimicrobial metal may be formulated into the adhesive casting solution and allowed to mix thoroughly. The solution is cast directly onto the backing material and the casting solvent is evaporated in an oven, leaving an adhesive film.
- a polyurethane matrix patch can be employed to deliver the antimicrobial metal to the mucosal membrane.
- the layers of this patch comprise a backing, a polyurethane drug/enhancer matrix, a membrane, an adhesive, and a release liner.
- the polyurethane matrix is prepared using a room temperature curing polyurethane prepolymer. Addition of water, alcohol, and drug to the prepolymer results in the formation of a tacky firm elastomer that can be directly cast onto the backing material. C. Sterilization
- Dressings, coatings, powders or formulations of the nanocrystalline antimicrobial metal formed with atomic disorder are preferably sterilized without applying excessive thermal energy, which can anneal out the atomic disorder, thereby reducing or eliminating a useful release of antimicrobial metal species.
- Gamma radiation is preferred for sterilizing such dressings, as discussed in WO 95/13704. Electron beam and ethylene oxide sterilization techniques can also be used.
- the sterilized dressings, coatings, powders or formulations should be sealed in packaging, containers or kits which limits moisture and light penetration to avoid additional oxidation or reduction of the antimicrobial metal.
- Polyester peelable pouches are exemplary.
- the shelf life of coatings or powders thus sealed is over one year. D. Formulating. Dosages and Treatment
- the nanocrystalline antimicrobial metals will be formulated from the active ingredient, namely nanocrystalline powders or coatings of the antimicrobial metals, or dissolved species from such powders or coatings, in the one or more of the formats set out above.
- Dressings or powders of the nanocrystalline antimicrobial metals may be applied directly to the mucosal membrane, or they may be formulated as set out below.
- the powder size might be controlled to less than 2 ⁇ m, more preferably to less than 1 ⁇ m.
- the amount of the nanocrystalline metal powder may range broadly from about 0.001% to about 30% by weight, but will more preferably fall in the range of from about 0.01 to 10% by weight, and most preferably in the range of about 0.1 to 5% by weight.
- Typical coating thicknesses are in the range of 150 to 3000 nm thick. Thicker coatings, up to 10,000 nm thick, can be used to generate powders of the antimicrobial metal. Coatings of the nanocrystalline antimicrobial metals may be very thin, or thick, depending on the desired duration of application on the patient.
- the amount of dissolved antimicrobial metal will typically range between about 0.001 to 10% by weight, more preferably 0.01 to 1% by weight.
- compositions may also include non- toxic, pharmaceutically acceptable carriers, diluents and excipients, suitable for topical application, as are well known, see for example Merck Index, Merck & Co., Rahway, N.J.; and Gilman et al., (eds) (1996) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8 th Ed., Pergamon Press.
- pharmaceutically acceptable carriers such as are well known, see for example Merck Index, Merck & Co., Rahway, N.J.; and Gilman et al., (eds) (1996) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8 th Ed., Pergamon Press.
- For standard dosages of conventional pharmacological agents see, e.g., Physicians Desk Reference (1997 Edition); and U.S. Pharmacopeia National Formulary (1995), United States Pharmacopeial Convention Inc., Rockville, Maryland.
- compositions of the nanocrystalline antimicrobial metals include various mixtures and combinations that can be applied topically and will permit even spreading and absorption into the cutaneous surfaces. Examples include sprays, mists, aerosols, lotions, creams, solutions, gels, ointments, pastes, emulsions, foams and suspensions.
- the active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- Topical preparations can be prepared by combining the antimicrobial metal powder with conventional pharmaceutically acceptable carriers commonly used in topical dry, liquid, cream and aerosol formulations.
- Ointment and creams can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- An exemplary base is water.
- Thickening agents can be used according to the nature of the base.
- Lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like.
- Powders can be formed with the aid of any suitable powder base, e.g., talc, lactose starch and the like.
- Drops can be formulated with an aqueous base or non-aqueous base, and can also include one or more dispersing agents, suspending agents, solubilizing agents, surface active agents and the like.
- Ointments, pastes, creams and gels also can contain excipients, such as starch, tragacanth, cellulose derivatives, silicones, bentonites, silicic acid, and talc, or mixtures thereof.
- Powders and sprays also can contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, and calcium silicates, or mixtures of these substances.
- Solutions of nanocrystalline antimicrobial metals can be converted into aerosols or sprays by any of the known means routinely used for making aerosol pharmaceuticals. In general, such methods comprise pressurizing or providing a means for pressurizing a container of the solution, usually with an inert carrier gas, and passing the pressurized gas through a small orifice.
- Sprays can additionally contain customary propellants, for instance inert gases such as nitrogen, carbon dioxide, argon or neon.
- ingredients are generally incorporated in topical formulations to improve cosmetic acceptability, and are optional ingredients in the formulations. Such ingredients are included only in therapeutically acceptable forms and amounts.
- ingredients are emulsifiers, emollients, thickening agents, solvents, hydrating or swelling agents, flavours, sweetening agents, surface active agents, colouring agents, anti-foaming agents, preservatives, fragrances, and fillers may also be added, as is well known in the art; for example, preservatives such as methyl paraben and propyl paraben, texturizing agents, thickeners, anticoagulants such as heparin, ⁇ -glucan, hormones, hyaluronic acid, immune potentiating agents such as adjuvants and cytokines such as epidermal growth factor, platelet derived growth factor, transforming growth factor and interleukins, and bone morphogenetic proteins, and the like.
- Polyvinyl alcohol is a particularly preferred gelling polymer and also acts as a texturizing agent, methyl or propyl parabens are particularly preferred preservatives. These other agents may be included in amounts in the range of 0.1 to 5 wt %.
- Surface active agents or foaming agents may be added to the formulations and are particularly advantageous for addition to liquid formulations for aerosol or foam applications, to form foams for applications such as to treat STD's or aerosols for application for respiratory disorders.
- Surface active agents are also useful for such coated substrates as dental floss.
- Exemplary surface active agents are listed in for instance WO 02/02128 to The Proctor & Gamble Company, published January 10, 2002, and in US Patent 5,875,799 to Petrus, issued March 2, 1999. Particularly useful are sodium lauryl sulfate, sodium lauroyl sarconsinate, sodium alkyl sulfate, and phospholipids such as lecithin and sphingomyelin.
- All agents must be non-toxic and physiologically acceptable for the intended purpose, and must not substantially interfere with the activity of the nanocrystalline antimicrobial metals so as to deleteriously affect the antimicrobial effect or the anti-inflammatory activity. Ingredients are thus only included in therapeutically acceptable amounts. Ingredients to be generally avoided or limited in the formulations of the present invention, at least in amounts greater than 0.01 wt %, are glycerin, glycerols, chloride salts, aldehydes, ketones, long chain alcohols, and triethanolamine.
- the dosage of the active ingredients depends upon many factors that are well known to those skilled in the art, for example, the particular form of the active ingredient, the condition being treated, the age, weight, and clinical condition of the recipient patient, and the experience and judgement of the clinician or practitioner administering the therapy.
- a therapeutically effective amount of the nanocrystalline antimicrobial metal provides either subjective relief of symptoms or an objectively identifiable improvement as noted by the clinician or other qualified observer.
- the dosing range varies with the metal used, its form, the route of administration and the potency of the particular compound.
- the dressing When the formulation is in the form of a dressing, the dressing is placed on the affected portion of the mucosal membrane and, depending on the degree of moisture at the membrane, may be further moistened with drops of sterile water or, for example 70% ethanol, in order to activate the coating for release of antimicrobial or noble metal species.
- the dressing may be then secured in place with an occlusive or semi-occlusive layer, such as an adhesive tape or polyurethane film, which keeps the dressing in a moist environment.
- the dressings are kept moist, at 100% relative humidity. Adding sterile water initially to activate the antimicrobial or noble metal coating is needed, and then as needed to maintain the dressing in a moist condition.
- Dressings may be changed as required for observation and cleaning. Preferably dressings are changed daily, but could be left longer, such as 3 days, and can provide a therapeutic effect for a much longer period of time.
- formulations such as occlusions, gels, pastes, ointments, creams, emulsions, foams, and liquids may be prepared in stable forms, or more preferably are prepared fresh from one or more phases, for instance in multi component kit form, so as to avoid aging and to maximize the therapeutic effectiveness of the antimicrobial metal component.
- Formulations are best used within about 30 days after combining the phases. Suitable kits or containers are well known for maintaining the phases of formulations separate until the time of use.
- the antimicrobial metal in powder or coated substrate form may be packages separately from therapeutically acceptable carriers, and possibly other ingredients for mixing at the time of use.
- the separate coated substrate may be in dressing or patch form for direct application, or may take other suitable forms to generate liquid formulations and the like, such as a coating on the inside surface of a vial or container, a liner, a porous shaped mesh, a filtering surface, a mesh, or a film.
- the antimicrobial metal may be provided in a "tea bag"-type infuser or pouch, for generating liquid formulations at the time of use.
- the tea bag-type infuser is advantageous in that the pouch may serve as a filter for small particulates of the powder that may be detrimental to administration for some applications such as aerosols for respiratory disorders.
- kits containing the dressing, coated substrate or powder may provide a sterile carrier such as water (and other ingredients) in a separate container in dosage specific amounts.
- a sterile carrier such as water (and other ingredients)
- kit is meant to refer to packaged formulations, whether the ingredients are in separate phases or mixed, and thus for example, may include a gel in a tube with all ingredients in admixture, or any formulation wherein the ingredients are separated from each other.
- Formulations for respiratory disorders may be delivered as dry powders in dry powder inhalers, or they may be formulated in liquid formulations for delivery in metered dose inhalers, aerosols, mists or sprays.
- the pH of the solution during dissolution may be lowered to less than pH 6.5, more preferably to the range of 3.5 to 6.5, with such acidifying agents as carbon dioxide (which generated carbonic acid in solution).
- This pH range will typically generate concentrations of silver from atomic disordered silver from 85 ⁇ g/ml to 370 ⁇ g/ml, and can be adjusted for different desired concentrations.
- Dissolution of the antimicrobial metal will typically raise the pH to 6.5 to 7.0.
- Administration as aerosols produces droplets preferably less than 10 ⁇ m in size, more preferably less than 5 ⁇ m in size, most preferably 1 - 3 ⁇ m in size.
- Control of the droplet size is important both to control the dosage delivered and to enhance delivery to the target tissues, e.g., where the aerosol is inhaled through the mouth, large droplets of about 10 ⁇ m tend to stay in the throat whereas small droplets (e.g., approximately 1-3 ⁇ m) tend to travel to the alveolar region of the lungs.
- droplet size can be regulated, to at least some extent, by the mechanical mister which is used to produce the aerosol.
- the aerosol's droplet size can be adjusted, to at least some extent, by modifying the surface tension of the solution.
- the solution of the antimicrobial metal typically has water as its solvent, and water has a relatively high surface tension, so it is relatively straightforward to create an aerosol having relatively small droplet size.
- Surface active agents can be added to the solution so as to reduce the surface tension of the solution, to create an aerosol having a relatively large droplet size.
- such surface active agents may comprise sodium alkyl sulfates, sodium lauryl sulfate, sodium lauroyl sarconsinate, phospholipids, e.g., lecithin, sphingomyelin, etc.
- solutions generated from powders of the antimicrobial metal should avoid inclusion of particulates larger than 2 ⁇ m, and more preferably no larger than l ⁇ m (i.e., submicron) to avoid deliterious immune responses or toxic effects.
- Larger particulates may be removed by, for example filtration.
- Particulates may be formed in the liquid and can be removed, for example by filtration.
- silver carbonates may be formed on reaction with the carbonic acid used to acidify the solution. Particulate generation may also be limited by diluting the carbonic acid in solution.
- the aerosol may be created by passing a liquid solution of the antimicrobial metal through a mechanical mister (e.g., a nebulizer) and may be applied directly with a pressurized pack (e.g., via a hand inhaler with a propellant such as carbon dioxide or other gas, with a valve metered dosage) or through some other delivery system (e.g., an oxygen tent, etc.).
- a mechanical mister e.g., a nebulizer
- a pressurized pack e.g., via a hand inhaler with a propellant such as carbon dioxide or other gas, with a valve metered dosage
- some other delivery system e.g., an oxygen tent, etc.
- the invention provides methods of treating, by administering a therapeutically effective amount of a nanocrystalline antimicrobial or noble metal powder, or a solution derived from a nanocrystalline antimicrobial or noble metal, as either a topical formulation, or as a coating on medical dressing, applied to the locally affected area of the mucosal membrane.
- a therapeutically effective amount may be determined by testing formulations containing the nanocrystalline antimicrobial or noble metals by in vitro or in vivo testing. Formulations may be applied one or more times a day.
- Dressings coated with the nanocrystalline antimicrobial or noble metals may be changed daily, or even less frequently, and should be kept in a moist condition with the addition of saline, alcohols, or more preferably sterile water, in order to release ions, atoms, molecules or clusters of the nanocrystalline metal, on a sustained basis.
- This example shows the preparation of a bilayer nanocrystalline silver coating on a dressing material.
- a high density polyethylene dressing, DELNETTM or CONFORMANT 2TM was coated with a silver base layer and a silver/oxide top layer to generate a coloured antimicrobial coating having indicator value.
- the coating layers were formed by magnetron sputtering under the conditions set out in Table 1. Table 1 - Sputtering conditions
- the resulting coating was blue in appearance. A fingertip touch was sufficient to cause a colour change to yellow.
- the base layer was about 900 nm thick, while the top layer was 100 nm thick.
- the coating was analyzed by nitric acid digestion and atomic absorption analysis to contain 0.24 +/- 0.04 mg silver per mg high density polyethylene.
- the coating was a binary alloy of silver (>97%) and oxygen with negligible contaminants, based on secondary ion mass spectroscopy.
- the coating as viewed by SEM, was highly porous and consisted of equiaxed nanocrystals organized into coarse columnar structures with an average grain size of 10 nm. Silver release studies in water demonstrated that silver was released continuously from the coating until an equilibrium concentration of about 66 mg L was reached (determined by atomic absorption), a level that is 50 to 100 times higher than is expected from bulk silver metal (solubility ⁇ lmg L).
- top layer By varying the coating conditions for the top layer to lengthen the sputtering time to 2 min, 15 sec, a yellow coating was produced.
- the top layer had a thickness of about 140 nm and went through a colour change to purple with a fingertip touch.
- a purple coating was produced by shortening the sputtering time to 1 min, to achieve a top layer thickness of about 65 nm. A fingertip touch caused a colour change to yellow.
- the dressing may be used with either the blue coating side or the silver side in the mucosal membrane facing position. For indicator value, it might be preferable to have the blue coating visible.
- the three layers were laminated together by ultasonic welding to produce welds between all three layers spaced at about 2.5 cm intervals across the dressing. This allowed the dressing to be cut down to about 2.5 cm size portions for smaller dressing needs while still providing at least one weld in the dressing portion.
- the coated dressings were sterilized using gamma radiation and a sterilization dose of 25 kGy.
- the finished dressing was packaged individually in sealed polyester peelable pouches, and has shown a shelf life greater than 1 year in this form.
- the coated dressings can be cut in ready to use sizes, such as 5.1 x 10.2 cm strips, before packaging. Alternatively, the dressings may be packaged with instructions for the patient or clinician to cut the dressing to size.
- Additional silver coated dressings were prepared in a full scale roll coater under conditions to provide coatings having the same properties set out above, as follows: a) the dressing material included a first layer of silver coated DELNET, as set out above, laminated to STRATEX, AET, 8.0NP 2 -A/QW, which is a layer of 100% rayon on a polyurethane film. b) Silver Foam Dressing - three layers of silver coated high density polyethylene prepared as above, alternating with two layers of polyurethane foam, L- 00562-6 Medical Foam, available from Rynel Ltd., Bootbay, Maine, USA.
- the HDPE mesh coated with silver can be used to generate solutions containing silver species for liquid formulations and the like, as set forth in examples below (AgHDPE). Similar coating conditions are used on substrates such as alginate and CMC as set out in later examples.
- Example 2 Preparation of Atomic Disordered Nanocrystalline Silver Powders
- Nanocrystalline silver coatings were prepared by sputtering silver in an oxygen- containing atmosphere directly onto an endless stainless steel belt of a magnetron sputtering roll coater, or onto silicon wafers on the belt.
- the belt did not need to be cooled.
- the coatings were scraped off with the belt with suspended metal scrapers as the belt rounded the end rollers.
- the coatings were scraped off with a knife edge.
- the sputtering conditions were as follows: Table 2 - Sputtering Conditions
- Target Size (indi vidual, 23 targets) : 15.24 cm X 1216.125 cm
- the powder had a particle size ranging from 2 ⁇ m to 100 ⁇ m, with grain or crystallite size of 8 to 10 nm (i.e., nanocrystalline), and demonstrated a positive rest potential.
- Silver solutions were prepared by immersing AgHDPE mesh from dressings prepared as in Example 1 in reverse osmosis water that had been pretreated with CO 2 in order to reduce the pH. Two different concentrations of silver solutions were prepared by this method, the concentrations being 85 ⁇ g/ml, and 318 ⁇ g/ml. Solutions of silver nitrate were also prepared to use as comparisons in the experiments. The concentrations of the silver nitrate were 103 ppm of silver and 295 ppm of silver as determined by Atomic Absorption Spectroscopy.
- the solutions were in turn placed in an ultrasonic nebulizer that created small droplets ' containing dissolved and suspended parts of the silver solution.
- the output from the nebulizer was directed into a chamber made from a stainless steel frame and base.
- Petri dishes containing Mueller Hinton agar streaked with 4 h old cultures of Pseudomonas aeruginosa and Staphylococcus aureus were exposed to the silver solution aerosols and the silver nitrate aerosols.
- the delivery of antimicrobial materials may most expeditiously be accomplished by using aerosols (e.g. treatment of pneumonia).
- aerosols e.g. treatment of pneumonia
- the drawback of aerosols is the requirement for a high concentration of the active ingredient to ensure that a sufficient amount is delivered to achieve the biological effect desired without causing problems with the carrier solvent (e.g. water).
- the equipment for producing an aerosol that contains the dissolved and suspended components of nanocrystalline silver form droplets of aerosol direct from the liquid form, and the aerosol droplets must be small enough to reach the lungs. This means the droplets should be less than approximately 10 ⁇ m.
- aerosol is not created by first evaporating the liquid then condensing it to form droplets. Rather, aerosols are generated by 1) mechanical disruption of the liquid, or 2) air under pressure passing through some form of orifice that combines the air and the liquid in a way that creates droplets instead of evaporating the liquid.
- the method used for the current tests was the mechanical method in the form of an ultrasonic nebulizer.
- an ultrasonic humidifier was used for convenience.
- the liquid containing the dissolved and suspended silver from the dressing of Example 1 was placed in the water reservoir of the humidifier.
- power was applied to the humidifier aerosol droplets of dissolved and suspended silver were generated and flowed from the output nozzle.
- a test chamber was constructed using a stainless steel frame with a transparent plastic covering.
- the frame was placed on a stainless steel base plate.
- the output nozzle from the humidifier was modified so that the aerosol could be directed into the chamber at a height of approximately 30 cm from the base.
- the plates and other test samples were placed on the stainless steel plate and exposed to the aerosol for a prescribed length of time.
- Solution 1 - A silver containing solution was prepared by immersing 518 sq. inches of the dressing from Example 1 in 1 L of reverse osmosis water, which was treated with CO 2 to maintain a pH of 6.5. After 20 minutes the concentration of silver in the water was 85 ⁇ g/ml.
- Solution 2 A solution containing 370 ⁇ g/ml of silver from a dressing from Example 1 was prepared as follows: 1 L of reverse osmosis water was purged with commercial grade carbon dioxide until the pH was 4.3.
- Solution 3 - Ag as AgNO 3 was prepared by dissolving 0.157 g of AgNO 3 into 1 L of reverse osmosis water and mixed until dissolved. The solution was analyzed by Atomic Absorption
- Solution 4 - Ag as AgNO 3 was prepared by dissolving 0.427 g of AgNO 3 into 1 L of reverse osmosis water and mixed until dissolved. The solution was analyzed by Atomic Absorption
- Petri dishes containing Mueller Hinton agar, were streaked with 4 h old cultures of Pseudomonas aeruginosa or Staphylococcus aureus. The plates were then weighed and their exposed outer surfaces were coated with Parafilm to prevent condensation from occurring on these surfaces. These plates were placed in the aerosol chamber uncovered. The ultrasonic nebulizer was then started and run for 53 minutes. The plates were then removed from the chamber, the plastic was removed and the dishes re-weighed so that the amount of moisture loss/gain could be determined.
- the dressing generated silver was effective in controlling the growth of both organisms while the silver nitrate only prevented the growth of P. aeruginosa. Viability tests showed that at the low concentration, neither form of silver was completely bacteriocidal although the poor growth on the dressing aerosol treated plates compared to the silver nitrate treated plates suggests that a significant log reduction occurred in the dressing aerosol treated plates.
- both dressing generated silver (370 ⁇ g/ml) and AgNO 3 (300 ⁇ g/ml) were effective at controlling P. aeruginosa. Since no re-growth occurred, it is assumed that the agent at this concentration were bactericidal. Silver generated from the dressing was more effective than AgNO 3 at controlling S. aureus. No re-growth occurred on any plates or in the broth indicating a total kill of the organism while in the AgNO 3 treatment, a large number of organisms grew at 16 h.
- a dose per unit area can be calculated. In each case for solution 1 the dose was 8.5 ⁇ g/sq. inch while for solution 2 the dose was 38 ⁇ g/sq. inch. These doses, on a per lung basis, would be less than 10 mg of silver per hour of treatment. Each hour of treatment with dressing generated silver aerosols appears to provide at least 48 h of protection. Therefore the dose per day, from the high concentration treatment, would be about 5 mg or a little less than the silver released by 2 sq. inches of SSD per day.
- a most significant advantage of using dressing generated silver may be the lack of a toxic cation such as NO 3 or sulfadiazine.
- the dressing generated aerosols are operative to transmit the antimicrobial activity of the dressings to remote sites. Furthermore, the dressing generated aerosols were more effective than comparable concentrations of silver nitrate.
- a solution was prepared by sparging CO 2 through 400 ml of reverse osmosis water for 30 minutes at a flow rate of 1 L/min.
- the beaker of water was covered with a piece of parafilm to assist in maintaining a saturated CO 2 environment. This process resulted in the pH of the water dropping to about 4.
- approximately 600 square inches of silver-coated net (AgHDPE) prepared as in Example 1 was added to the water and stirred for approximately 40 minutes resulting in an elevation of the pH to approximately 6.5.
- the solution was then transferred to a medical nebulizer and connected to an oxygen cylinder with a flow rate of 10 L/min.
- the outflow of the nebulizer was connected to a sealed animal chamber housing the rats to be dosed. Only the "test" rats (15 randomly assigned animals) received the dosing. The rats received two, one-hour aerosol administrations of the solution on the day of infection. Thereafter, the test rats were dosed three times per day for an additional three days, ii) Animals
- the bacteria used for infection of these animals were Pseudomonas aeruginosa strain 579. The dose was previously titrated to ascertain that a dose of up to 10 10 CFU was not lethal for the animals. The bacteria were grown overnight in Tryptic soy broth, washed once in sterile PBS, and re-suspended in a 1/10 volume of sterile PBS. iv) Infection
- the rats were anesthetized by inhalation of 2% halothane.
- a 50 ⁇ L volume of bacterial suspension was intratracheally administered into the bronchi of each rat. This was performed non-surgically on intubated animals.
- the infection process resulted in the instillation of approximately 2 X 10 9 CFU into the lungs of each animal, iv) Sampling
- the dosing chamber is not perfect. Although significant amounts of mist are generated into the chamber, the rats tend to lie on top of one another and are probably exposed to vastly different levels of the silver mist, b) Results i) Pulmonary Bacterial Levels
- the method employed for exposing the rats to the mist is also prone to significant variation due to the piling up of the rats and the resultant inconsistent exposure to the silver- containing mist.
- the silver analyses suggested that a reasonably uniform dose of silver was achieved when only a few animals were present within the dosing chamber.
- a solution from nanocrystalline silver coated dressings (AgHDPE) from Example 1 was prepared by sparging CO 2 through 1000 ml of reverse osmosis water using commercial CO 2 Soda Syphon Charger. This process resulted in the pH of the water dropping to about 4. At this point, approximately 333 ml of the carbonated water was decanted into a plastic bottle and 333 square inches of nanocrystalline silver-coated net was added to the water. The nanocrystalline silver-coated net and water were placed in 37 ° C shaker incubator and shaken at 180 RPM for 30 minutes to elevate the pH to approximately 5.8. The solution was then transferred to a beaker and stirred vigorously for 2 minutes to raise the pH to approximately at 7.3.
- the dissolution solution was transferred to a commercial nebulizer which was connected to a Medical air cylinder with a flow rate of approx. 20 L/min.
- the outflow of the nebulizer was connected to a animal chamber housing the rats to be dosed. Only the "test" rats (12 randomly assigned animals) received the dosing. The rats received two - V ⁇ hour aerosol administrations of the test solution on the day of infection. Thereafter, the test rats were dosed 3 times per day for an additional one and a half days.
- the bacteria used for infection of these animals were Pseudomonas aeruginosa strain 5588. The dose was previously titrated to ascertain that a dose of up to 10 9 CFU was not lethal for the animals.
- the bacteria were grown overnight in Tryptic soy broth, washed once in sterile PBS and resuspend in sterile PBS. The final concentration of the inoculum was 4 X 10 9 CFU/ml.
- the rats were anesthetized by inhalation of 2% halothane.
- a 400 ⁇ L volume of bacterial suspension was intratracheally administered into the bronchi of each rat. This was performed non-surgically on intubated animals.
- the infection process resulted in the instillation of approximately 10 9 CFU into the lungs of each animal.
- Histopathology was scored (0-4) based upon the degree of consolidation and inflammation (neutrophil infiltration). The entire right middle lobes of all rats were collected for histopathology. As whole lobes were selected there was no bias toward any sample. All samples were fixed in neutral buffered formalin at the time the lung was removed from the thorax. It was fixed overnight, dehydrated and embedded in wax. Sections were obtained which were hydrated and stained with haematoxylin and eosin.
- Both the control and the Tobramycin treated rats had similar pathology. These are outlined in Table 6. At 24 and 48 hours severe infiltration of polymorphonuclear leukocytes (PMN's) into the interstitial spaces of the lung was observed. These cellular elements could also be identified in alveolar and bronchiolar spaces but to a lesser extent. The pulmonary vessels were dilated and the alveolar spaces were filled with proteinaceous material. The silver-nebulized rats had occasional infiltration of PMN's and no evidence of accumulation of fluids in alveolar or bronchiolar spaces.
- PMN's polymorphonuclear leukocytes
- nanocrystalline silver reduced bacterial colonization in Pseudomonas infected lungs reduced injury as determined by gross pathology (consolidation, hemorrhage, edema) in Pseudomonas infected lungs. Further, the nanocrystalline silver delivered by aerosol reduced pulmonary inflammation (primarily PMN infiltration) in Pseudomonas infected lungs compared to Tobramycin (IM).
- IM Tobramycin
- a solution was prepared by sparging CO 2 through 1000 ml of reverse osmosis water using commercial CO 2 Soda Syphon Charger. This process results in the pH of the water dropping to about 4. At this point, approximately 333 ml of the carbonated water was decanted into a plastic bottle and 333 square inches of nanocrystalline silver-coated net was added to the water. The nanocrystalline silver-coated net and water were placed in 37 ° C shaker incubator and shaken at 180 RPM for 30 minutes to elevate the pH to approximately 5.8. The solution was then transferred to a beaker and stirred vigorously for 2 minutes to raise the pH to approximately at 7.3. The solution had a final silver concentration of approximately 400 ppm.
- Test solutions of silver nitrate (400 ppm) and silver acetate (400 ppm) were prepared by dissolving the silver salts in deionized water.
- the dissolution solutions were transferred to commercial nebulizers which were connected to a Medical air cylinder with a flow rate of approx. 20 L/min.
- the outflows of the nebulizers were connected to an animal chamber housing the rats to be dosed. All rats (40 randomly assigned animals) received the dosing.
- the rats received two - Vz hour aerosol administrations of the test solutions on the day of infection. Thereafter, the test rats were dosed 3 times per day for an additional one and a half days.
- the bacteria used for infection of 20 these animals were Pseudomonas aeruginosa strain 5588. The dose was previously titrated to ascertain that a dose of up to 10 9 CFU was not lethal for the animals.
- the bacteria were grown overnight in Tryptic soy broth, washed once in sterile PBS and resuspend in sterile PBS. The final concentration of the inoculum was 4 X 10 9 CFU/ml.
- the rats were anesthetized by inhalation of 2% halothane.
- a 400 ⁇ L volume of bacterial suspension was intratracheally administered into the bronchi of each rat. This was performed non-surgically on intubated animals. The infection process resulted in the instillation of approximately 10 9 CFU into the lungs of each animal.
- Histopathology was scored (0-4) based upon the degree of consolidation and inflammation (neutrophil infiltration). The entire right middle lobes of all rats were collected for histopathology. As whole lobes were selected there was no bias toward any sample. All samples were fixed in neutral buffered formalin at the time the lung was removed from the thorax. It was fixed overnight, dehydrated and embedded in wax. Sections were obtained which were hydrated and stained with haematoxylin and eosin.
- Example 7 Treatment of an Infected Throat with a Nanocrystalline Silver Derived Solution
- Example 8 Preparation of Gels
- No. 3 An alginate fibrous substrate was directly coated with an atomic disordered nanocrystalline silver coating using magnetron sputtering conditions similar to those set forth in Example 1.
- the alginate (5.7 g) was added to 100 ml volume of water to create a gel.
- This material was tested using the method of No. 1.
- the material generated a 5.2 logarithmic reduction of Pseudomonas aeruginosa, demonstrating that the gel had a significant bactericidal effect.
- the well was filled with either 0.1 ml of the silver containing gel, a mupirocin containing cream or a mupirocin containing ointment.
- the Petri plates were then incubated for 24 h and the diameter of the zone of inhibition was measured and recorded.
- the silver containing gel produced 9 mm zone of inhibition against both Pseudomonas aeruginosa and Staphylococcus aureus, while the mupirocin cream and ointment produced 42 and 48 mm zones against Staphylococcus aureus and 0 mm zones against Pseudomonas aeruginosa.
- the silver containing gel reduced the Pseudomonas aeruginosa and Staphylococcus aureus properties by 4.4 and 0.6 log reductions, respectively, showing good bactericidal activity.
- the mupirocin cream and ointment generated 0.4 and 0.8, and 0.8 and 1.6, log reductions against Staphylococcus aureus and Pseudomonas aeruginosa, respectively.
- the silver gel had both a greater bactericidal effect and spectrum of activity than the mupirocin containing products.
- Nos. 5-10 The formula for Nos. 5-10 are summarized in Table 7. Zones of inhibitions were determined as in No. 4 and log reductions as in No. 1. All formulae provided a broader spectrum of activity and a greater bactericidal effect than did mupirocin in a cream or ointment form. The mupirocin cream produced zones of inhibition of 42 and 0, and log reduction of 0.4 and 0.8, against Staphylococcus aureus and Pseudomonas aeruginosa, respectively.
- No. 11 - A commercially available gel (glyceryl polymethacrylate) was blended with nanocrystalline silver powder from Example 2 to produce a gel with a silver content of 0.1%. This gel was tested as in Nos. 5-10 and was found to produce zones of 15 mm against both Staphylococcus aureus and Pseudomonas aeruginosa. Log reductions of 1.7 and >5 were produced against Staphylococcus aureus and Pseudomonas aeruginosa. This gel product had a greater spectrum of activity than did mupirocin cream or ointment.
- the silver gel solutions of No. 1 - 11 can be used as gel formulations for the treatment of mucosal membranes in accordance with the present invention.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02721902.1A EP1383520B1 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of inflammation of the mucosa |
JP2002582958A JP2004525980A (en) | 2001-04-23 | 2002-04-23 | Use of metals for treatment of mucous membranes |
CA 2445729 CA2445729C (en) | 2001-04-23 | 2002-04-23 | Use of metals to treat mucosal membranes |
AU2002252879A AU2002252879B2 (en) | 2001-04-23 | 2002-04-23 | Use of metals to treat mucosal membranes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28588401P | 2001-04-23 | 2001-04-23 | |
US09/840,637 US7008647B2 (en) | 2001-04-23 | 2001-04-23 | Treatment of acne |
US60/285,884 | 2001-04-23 | ||
US09/840,637 | 2001-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002085385A2 true WO2002085385A2 (en) | 2002-10-31 |
WO2002085385A3 WO2002085385A3 (en) | 2003-01-16 |
Family
ID=26963436
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2002/000548 WO2002085386A2 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
PCT/CA2002/000546 WO2002085384A2 (en) | 2001-04-23 | 2002-04-23 | Lubricious coatings for substrates |
PCT/CA2002/000549 WO2002085387A2 (en) | 2001-04-23 | 2002-04-23 | A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
PCT/US2002/012690 WO2002085299A2 (en) | 2001-04-23 | 2002-04-23 | Therapeutic treatments using the direct application of antimicrobial metal compositions |
PCT/CA2002/000547 WO2002085385A2 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2002/000548 WO2002085386A2 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
PCT/CA2002/000546 WO2002085384A2 (en) | 2001-04-23 | 2002-04-23 | Lubricious coatings for substrates |
PCT/CA2002/000549 WO2002085387A2 (en) | 2001-04-23 | 2002-04-23 | A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
PCT/US2002/012690 WO2002085299A2 (en) | 2001-04-23 | 2002-04-23 | Therapeutic treatments using the direct application of antimicrobial metal compositions |
Country Status (9)
Country | Link |
---|---|
US (9) | US6989156B2 (en) |
EP (4) | EP1383521A2 (en) |
JP (4) | JP2004529930A (en) |
AT (1) | ATE322274T1 (en) |
AU (4) | AU2002252881B2 (en) |
CA (4) | CA2445734A1 (en) |
DE (1) | DE60210441T2 (en) |
ES (1) | ES2261659T3 (en) |
WO (5) | WO2002085386A2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004075920A1 (en) * | 2003-02-26 | 2004-09-10 | Otsuka Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition for lung administration |
DE10359338A1 (en) * | 2003-12-17 | 2005-07-21 | Heraeus Kulzer Gmbh | Antimicrobial nanosilver additive for polymerizable dental materials |
EP1575552A2 (en) * | 2002-10-22 | 2005-09-21 | Nucryst Pharmaceuticals Corp. | Metal-containing materials, compositions and methods |
EP1842524A1 (en) * | 2004-12-13 | 2007-10-10 | APT Co., Ltd. | Cleaning liquid for oral cavity |
WO2008043396A1 (en) * | 2006-10-12 | 2008-04-17 | Nm Tech Nanomaterials Microdevice Technology Ltd. | Material, item and products comprising a composition having anti-microbial properties |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8158137B2 (en) | 2006-04-24 | 2012-04-17 | NM Tech Nanomaterials and Microdevices Technology Limited | Functional nanomaterials with antibacterial and antiviral activity |
US8178122B2 (en) | 2006-06-14 | 2012-05-15 | Nm Tech Nanomaterials And Microdevices Technology Ltd. | Use of nanomaterials based on titanium dioxide and zirconium diozide as coatings for osteointegrated biomedical prostheses, and osteointegrated biomedical prostheses prepared therewith |
RU2452498C2 (en) * | 2010-07-20 | 2012-06-10 | Общество с ограниченной ответственностью "Научно-производственное объединение "Ликом" | Method for preparing anti-tuberculosis drug |
US8309117B2 (en) | 2002-12-19 | 2012-11-13 | Novartis, Ag | Method for making medical devices having antimicrobial coatings thereon |
US8519146B2 (en) * | 2004-09-07 | 2013-08-27 | The University Of Akron | Metal complexes of N-heterocyclic carbenes as antibiotics |
WO2014066850A2 (en) * | 2012-10-26 | 2014-05-01 | Nanocomposix, Inc. | Metastable silver nanoparticle composites |
US8802154B2 (en) | 2010-08-27 | 2014-08-12 | Sienna Labs, Inc. | Thermal treatment of a pilosebaceous unit with nanoparticles |
US8906883B2 (en) | 2009-06-10 | 2014-12-09 | Exthera Ab | Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate |
WO2018009998A1 (en) * | 2016-07-14 | 2018-01-18 | Luiz Francisco Pianowski | Antimicrobial mucosal formulation and use of the antimicrobial mucosal formulation |
CN109731103A (en) * | 2019-01-20 | 2019-05-10 | 桂林理工大学 | P-zeolite-chitin-sodium alginate-potassium diformate sustained-release antibacterial agent preparation method |
US10537640B2 (en) | 2010-08-27 | 2020-01-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
US10537661B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
US10537658B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
US10688126B2 (en) | 2012-10-11 | 2020-06-23 | Nanocomposix, Inc. | Silver nanoplate compositions and methods |
Families Citing this family (291)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9119705B2 (en) | 1998-06-08 | 2015-09-01 | Thermotek, Inc. | Method and system for thermal and compression therapy relative to the prevention of deep vein thrombosis |
WO2005000324A2 (en) * | 2003-06-03 | 2005-01-06 | American Biotech Labs | Colloidal silver composition having antimicrobial properties |
US7135195B2 (en) * | 1999-06-01 | 2006-11-14 | American Silver, Llc | Treatment of humans with colloidal silver composition |
US7179849B2 (en) * | 1999-12-15 | 2007-02-20 | C. R. Bard, Inc. | Antimicrobial compositions containing colloids of oligodynamic metals |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US7427416B2 (en) * | 2000-07-27 | 2008-09-23 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions using metal-containing materials |
US7008647B2 (en) * | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
US20060115541A1 (en) * | 2000-07-27 | 2006-06-01 | Gillis Scott H | Treatment of bladder conditions |
US20030185901A1 (en) * | 2000-07-27 | 2003-10-02 | Burrell Robert E. | Methods of treating conditions with a metal-containing material |
DE10043151A1 (en) * | 2000-08-31 | 2002-03-28 | Peter Steinruecke | Bone cement with antimicrobial effectiveness |
WO2002085386A2 (en) * | 2001-04-23 | 2002-10-31 | Nucryst Pharmaceuticals Corp. | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
US20040092890A1 (en) * | 2001-05-10 | 2004-05-13 | Ash Stephen R. | Catheter lock solution including a photo-oxidant |
AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
DE10146050B4 (en) * | 2001-09-18 | 2007-11-29 | Bio-Gate Ag | Process for the preparation of an antimicrobial adhesive and coating material |
JP3795364B2 (en) * | 2001-09-27 | 2006-07-12 | シャープ株式会社 | Integrated circuit and receiver |
US7820284B2 (en) | 2001-12-03 | 2010-10-26 | C.R. Bard Inc. | Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same |
TWI255224B (en) * | 2002-01-09 | 2006-05-21 | Novartis Ag | Polymeric articles having a lubricious coating and method for making the same |
US7270653B2 (en) * | 2002-02-20 | 2007-09-18 | Abbott Research Group | Methods of treating abnormal biological conditions using metal oxides |
US6589216B1 (en) | 2002-02-20 | 2003-07-08 | Abbott Research Group, Inc. | Vaginal douches, vaginal douche applicators and methods of vaginal douching |
US8118789B2 (en) * | 2002-02-20 | 2012-02-21 | Abbott Research Group, Inc. | Deodorizer devices and systems for controlling perspiration-related body odor |
US7201925B2 (en) * | 2002-04-23 | 2007-04-10 | Nueryst Pharmaceuticals Corp. | Treatment of ungual and subungual diseases |
DE10392979D2 (en) * | 2002-06-21 | 2005-07-14 | Continental Teves Ag & Co Ohg | Printed circuit board for electronic vehicle control units |
US6865810B2 (en) * | 2002-06-27 | 2005-03-15 | Scimed Life Systems, Inc. | Methods of making medical devices |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
US20040101553A1 (en) * | 2002-08-02 | 2004-05-27 | Transave, Inc. | Platinum aggregates and process for producing the same |
US8404751B2 (en) * | 2002-09-27 | 2013-03-26 | Hallux, Inc. | Subunguicide, and method for treating onychomycosis |
US7485259B2 (en) * | 2002-10-08 | 2009-02-03 | Eldred Bradley J | Organic compound and metal ion synergistic disinfection and purification system and method of manufacture |
EP1576528A4 (en) * | 2002-10-09 | 2011-05-18 | California Inst Of Techn | Sensor web |
AU2003286575A1 (en) * | 2002-10-22 | 2004-05-13 | Nucryst Pharmaceuticals Corp. | Prophylactic treatment methods |
US8066854B2 (en) * | 2002-12-18 | 2011-11-29 | Metascape Llc | Antimicrobial coating methods |
US8409618B2 (en) * | 2002-12-20 | 2013-04-02 | Kimberly-Clark Worldwide, Inc. | Odor-reducing quinone compounds |
US7666410B2 (en) | 2002-12-20 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Delivery system for functional compounds |
US20040151716A1 (en) * | 2003-02-03 | 2004-08-05 | Hamer Richard A. | Material and method for treating microbial mediated dermatological conditions |
ES2282529T3 (en) * | 2003-02-03 | 2007-10-16 | Hans-Dietrich Dr.Techn. Polaschegg | COMPOSITION FOR THE PREVENTION OF AN INFECTION DUE TO A PERMANENT DEVICE. |
US20040156874A1 (en) * | 2003-02-11 | 2004-08-12 | Bradley Pharmaceuticals, Inc. | Urea- a topical anti-inflammatory |
US20040180093A1 (en) * | 2003-03-12 | 2004-09-16 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US7488757B2 (en) * | 2003-03-24 | 2009-02-10 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
US20040236290A1 (en) * | 2003-04-23 | 2004-11-25 | Zimmermann Stephan A. | Minimally invasive vascular apparatus modified to minimize scarring at introduction site |
US6874165B2 (en) * | 2003-05-19 | 2005-04-05 | Mao-Sheng Lee | Modified NBR gloves |
HUE045608T2 (en) * | 2003-06-06 | 2020-01-28 | Univ Texas | Antimicrobial flush solutions |
DE10328261B4 (en) * | 2003-06-23 | 2007-10-25 | Beiersdorf Ag | Disinfecting coating with silver coating and its use |
NZ543643A (en) * | 2003-06-23 | 2007-09-28 | Beiersdorf Ag | Antimicrobial wound dressing with two layers and antimicrobial metal between layers but not on exterior |
US7480530B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Device for treatment of barrier membranes |
US8734421B2 (en) * | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
US20050025817A1 (en) * | 2003-07-03 | 2005-02-03 | Bhatia Kuljit S. | Delivery system for topical medications |
US8574278B2 (en) * | 2006-05-09 | 2013-11-05 | Thermotek, Inc. | Wound care method and system with one or both of vacuum-light therapy and thermally augmented oxygenation |
US8128672B2 (en) | 2006-05-09 | 2012-03-06 | Thermotek, Inc. | Wound care method and system with one or both of vacuum-light therapy and thermally augmented oxygenation |
DK200301128A (en) * | 2003-08-05 | 2005-02-06 | Thomsen Joern Oddershede | Grant Preparation |
US20050028563A1 (en) * | 2003-08-08 | 2005-02-10 | Milliken & Company | Garment for use with sensitive skin, and method and fabric for us in making same |
DE10340277B4 (en) * | 2003-08-29 | 2006-11-23 | Bio-Gate Bioinnovative Materials Gmbh | Personal care products containing silver agglomerates |
US20050054774A1 (en) * | 2003-09-09 | 2005-03-10 | Scimed Life Systems, Inc. | Lubricious coating |
US7794737B2 (en) | 2003-10-16 | 2010-09-14 | Kimberly-Clark Worldwide, Inc. | Odor absorbing extrudates |
US7879350B2 (en) | 2003-10-16 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using colloidal nanoparticles |
US7678367B2 (en) | 2003-10-16 | 2010-03-16 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified particles |
US20050123621A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
US20050123590A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Wound dressings and methods |
US7745509B2 (en) * | 2003-12-05 | 2010-06-29 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
WO2005058199A1 (en) * | 2003-12-16 | 2005-06-30 | Avery Dennison Corporation | Electrostatically self-assembled antimicrobial coating for medical applications |
GB0401821D0 (en) * | 2004-01-28 | 2004-03-03 | Qinetiq Nanomaterials Ltd | Method of manufacture of polymer composites |
US20050256553A1 (en) * | 2004-02-09 | 2005-11-17 | John Strisower | Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation |
US7457667B2 (en) * | 2004-02-19 | 2008-11-25 | Silverleaf Medical Products, Inc. | Current producing surface for a wound dressing |
US7662176B2 (en) * | 2004-02-19 | 2010-02-16 | Vomaris Innovations, Inc. | Footwear apparatus and methods of manufacture and use |
US20050196463A1 (en) * | 2004-03-03 | 2005-09-08 | Stiles James Alexander R. | NO-containing complexes |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
US20050249822A1 (en) * | 2004-03-18 | 2005-11-10 | Transave, Inc. | Administration of cisplatin by inhalation |
US20050271746A1 (en) * | 2004-05-18 | 2005-12-08 | Abbott Chun L | Topical treatments for abnormal biological conditions and method of topically treating such conditions |
US7758892B1 (en) * | 2004-05-20 | 2010-07-20 | Boston Scientific Scimed, Inc. | Medical devices having multiple layers |
WO2005112957A1 (en) * | 2004-05-21 | 2005-12-01 | Transave, Inc. | Treatment of lung diseases and pre-lung disease conditions |
DE102004031955A1 (en) * | 2004-06-24 | 2006-01-12 | Paul Hartmann Ag | wound dressing |
US20060002967A1 (en) * | 2004-07-01 | 2006-01-05 | Smestad Thomas L | Resorbable implant with lubricious coating |
US10765785B2 (en) | 2004-07-19 | 2020-09-08 | Thermotek, Inc. | Wound care and infusion method and system utilizing a therapeutic agent |
US10016583B2 (en) | 2013-03-11 | 2018-07-10 | Thermotek, Inc. | Wound care and infusion method and system utilizing a thermally-treated therapeutic agent |
US20060035039A1 (en) * | 2004-08-12 | 2006-02-16 | 3M Innovative Properties Company | Silver-releasing articles and methods of manufacture |
US20060034899A1 (en) * | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
CN2734238Y (en) * | 2004-08-25 | 2005-10-19 | 任晓艳 | Nano silver coated suture line |
US20060068024A1 (en) * | 2004-09-27 | 2006-03-30 | Schroeder Kurt M | Antimicrobial silver halide composition |
US20060246124A1 (en) * | 2004-11-08 | 2006-11-02 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
MX2007006190A (en) * | 2004-11-23 | 2008-01-22 | Internat Bio Therapeutic Res Inc | Method of delivery of therapeutic metal ions, alloys and salts. |
MX2007006726A (en) * | 2004-12-06 | 2008-03-10 | Novacentrix Corp | Anti-viral uses of metal nanomaterial compositions. |
US7749529B2 (en) * | 2005-02-08 | 2010-07-06 | Ash Access Technology, Inc. | Catheter lock solution comprising citrate and a paraben |
US20080202967A1 (en) * | 2005-02-23 | 2008-08-28 | Kerryne Krause-Neufeldt | Cosmetic Product |
DE102005008416B4 (en) * | 2005-02-24 | 2011-09-29 | Lohmann & Rauscher Gmbh & Co. Kg | Process for the purification of marine collagen |
US8864730B2 (en) | 2005-04-12 | 2014-10-21 | Rochester Medical Corporation | Silicone rubber male external catheter with absorbent and adhesive |
US8399027B2 (en) * | 2005-04-14 | 2013-03-19 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
CN101171040A (en) * | 2005-05-02 | 2008-04-30 | 科洛普拉斯特公司 | A method for sterilising a medical device having a hydrophilic coating |
US20060275223A1 (en) * | 2005-06-02 | 2006-12-07 | Burr James B | Erythritol compositions for teeth and gums |
BRPI0613622A2 (en) * | 2005-07-21 | 2017-05-02 | Fmc Biopolymer As | medical device |
WO2007013100A1 (en) * | 2005-07-26 | 2007-02-01 | Virchow Biotech Private Limited | Gel formulation comprising platelet derived growth factor |
DE102005041005B4 (en) | 2005-08-29 | 2022-10-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Biocidal composition containing nanoparticulate silver, the use of this composition and a method for the production of biocidal products using this composition |
US20070185432A1 (en) * | 2005-09-19 | 2007-08-09 | Transport Pharmaceuticals, Inc. | Electrokinetic system and method for delivering methotrexate |
JP5208752B2 (en) * | 2005-10-18 | 2013-06-12 | オーガノジェネシス・インコーポレイテッド | Antibacterial collagen construct |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US20070190181A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously |
US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
EP1954327A4 (en) * | 2005-12-01 | 2012-03-28 | Innograft Llc | Method for ionically cross-linking polysaccharide material for thin film applications and products produced therefrom |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US20070166399A1 (en) * | 2006-01-13 | 2007-07-19 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
US20070166344A1 (en) * | 2006-01-18 | 2007-07-19 | Xin Qu | Non-leaching surface-active film compositions for microbial adhesion prevention |
AU2007209856B2 (en) * | 2006-02-01 | 2013-06-13 | Hollister Incorporated | Methods of applying a hydrophilic coating to a substrate, and substrates having a hydrophilic coating |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
PL1993569T3 (en) | 2006-02-03 | 2014-11-28 | Obagi Cosmeceuticals Llc | Anti-aging treatment using copper and zinc compositions |
US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7687650B2 (en) * | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
GB0603487D0 (en) * | 2006-02-22 | 2006-04-05 | Agt Sciences Ltd | Delivery means |
US20070212425A1 (en) * | 2006-03-09 | 2007-09-13 | Barna Ivan J | Cidal formulations and methods of use |
US20070224288A1 (en) * | 2006-03-22 | 2007-09-27 | Kiss Nail Products, Inc. | Antibacterial gel coating and pedicure spa with antibacterial function |
US20070224244A1 (en) * | 2006-03-22 | 2007-09-27 | Jan Weber | Corrosion resistant coatings for biodegradable metallic implants |
US20100048451A1 (en) * | 2006-04-06 | 2010-02-25 | Taro Pharmaceuticals North America, Inc. | Novel spill-resistant formulations comprising hydrocolloidal polymers |
JP5049268B2 (en) * | 2006-04-07 | 2012-10-17 | 久光製薬株式会社 | Microneedle device and transdermal drug administration device with microneedle |
US8048150B2 (en) * | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8273381B1 (en) | 2006-04-14 | 2012-09-25 | Auburn University | Compositions for and methods of controlling olfactory responses to odorants |
US20070292397A1 (en) * | 2006-06-19 | 2007-12-20 | Mcnulty Amy K | Method for the detection and neutralization of bacteria |
WO2007149868A2 (en) * | 2006-06-20 | 2007-12-27 | The Regents Of The University Of California | Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles |
US20080014247A1 (en) * | 2006-06-30 | 2008-01-17 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
US8197452B2 (en) * | 2006-07-28 | 2012-06-12 | Becton, Dickinson And Company | Vascular access device non-adhering surfaces |
US8512294B2 (en) * | 2006-07-28 | 2013-08-20 | Becton, Dickinson And Company | Vascular access device antimicrobial materials and solutions |
US20080027410A1 (en) * | 2006-07-28 | 2008-01-31 | Becton, Dickinson And Company | Vascular access device non-adhering membranes |
EP2054537A2 (en) | 2006-08-02 | 2009-05-06 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
WO2008034048A2 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprosthesis with biostable inorganic layers |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
WO2008034007A2 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices |
US20080071353A1 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Scimed, Inc. | Endoprosthesis containing magnetic induction particles |
JP2010503494A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
JP2010503490A (en) * | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adjustable surface features |
WO2008034031A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
WO2008036554A2 (en) * | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
EP2073764A2 (en) * | 2006-09-18 | 2009-07-01 | Boston Scientific Limited | Controlling biodegradation of a medical instrument |
EP2068962B1 (en) * | 2006-09-18 | 2013-01-30 | Boston Scientific Limited | Endoprostheses |
US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
US20100098949A1 (en) * | 2006-10-18 | 2010-04-22 | Burton Scott A | Antimicrobial articles and method of manufacture |
US20080097577A1 (en) * | 2006-10-20 | 2008-04-24 | Boston Scientific Scimed, Inc. | Medical device hydrogen surface treatment by electrochemical reduction |
US20080103459A1 (en) * | 2006-10-30 | 2008-05-01 | Anthony Di Salvo | Enzyme inhibition using nanoparticles |
US20080122582A1 (en) * | 2006-11-29 | 2008-05-29 | Texas Instruments Incorporated | Location Based Portable Device Feature Disabler |
US20080132991A1 (en) * | 2006-11-30 | 2008-06-05 | Leonard Pinchuk | Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom |
US20080147734A1 (en) * | 2006-12-18 | 2008-06-19 | Cuticeuticals, Inc | Method of topical steroidal organization |
ES2506144T3 (en) | 2006-12-28 | 2014-10-13 | Boston Scientific Limited | Bioerodible endoprosthesis and their manufacturing procedure |
WO2008097661A1 (en) * | 2007-02-09 | 2008-08-14 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
US20080221533A1 (en) * | 2007-03-09 | 2008-09-11 | Anthem Orthopaedics Llc | Implantable device with bioabsorbable layer, kit and method for use therewith, and apparatus for preparing same |
US20080226701A1 (en) * | 2007-03-15 | 2008-09-18 | John Deignan | Medicated patches |
EP2155324A1 (en) * | 2007-04-20 | 2010-02-24 | Nitric Biotherapeutics, Inc. | A single use applicator cartridge for an electrokinetic delivery system and method for self administration of medicaments |
US20100069957A1 (en) * | 2007-04-25 | 2010-03-18 | Ferass Abuzaina | Coated Filaments |
US8309222B2 (en) * | 2007-04-25 | 2012-11-13 | Covidien Lp | Coated filaments |
KR20080070482A (en) * | 2007-05-31 | 2008-07-30 | (주)디딤바이오텍 | A lubricating composition comprising agents which induce the mucosal immunity and a preparation method thereof |
WO2008157485A1 (en) * | 2007-06-15 | 2008-12-24 | Transport Pharmaceuticals, Inc. | Current concentration system and method for electrokinetic delivery of medicaments |
US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
US20080319371A1 (en) * | 2007-06-19 | 2008-12-25 | Transport Pharmaceuticals, Inc. | Method and system for treating of onychomycosis with an applicator having a gel medicament layer |
JP5159183B2 (en) * | 2007-06-22 | 2013-03-06 | アイノベックス株式会社 | Composition for improvement or treatment of infertility |
DE102007031650A1 (en) | 2007-07-06 | 2009-01-08 | Stada Arzneimittel Ag | Dermatology for the treatment and / or care of the skin in atopic dermatitis |
US8052745B2 (en) * | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
CA2701009C (en) * | 2007-09-28 | 2017-03-21 | Johnson & Johnson Consumer Companies, Inc. | Electricity-generating particulates and the use thereof |
ATE510455T1 (en) * | 2007-10-03 | 2011-06-15 | 3M Innovative Properties Co | METHOD FOR LIMITING MICROORGANISM GROWTH |
ES2319064B1 (en) * | 2007-10-05 | 2010-02-15 | Universidad De Santiago De Compostela | USE OF ATOMIC QUANTIC CLUSTERS (AQCS) AS ANTIMICROBIALS AND BIOCIDES. |
US20110230973A1 (en) * | 2007-10-10 | 2011-09-22 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US8608049B2 (en) * | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US20090143855A1 (en) * | 2007-11-29 | 2009-06-04 | Boston Scientific Scimed, Inc. | Medical Device Including Drug-Loaded Fibers |
WO2009079389A2 (en) * | 2007-12-14 | 2009-06-25 | Boston Scientific Limited | Drug-eluting endoprosthesis |
US20090163887A1 (en) * | 2007-12-20 | 2009-06-25 | Arehart Kelly D | Odor control cellulose granules with quinone compounds |
WO2009085651A1 (en) | 2007-12-20 | 2009-07-09 | Nucryst Pharmaceuticals Corp. | Metal carbonate particles for use in medicine and methods of making thereof |
US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
US20090187256A1 (en) * | 2008-01-21 | 2009-07-23 | Zimmer, Inc. | Method for forming an integral porous region in a cast implant |
US20090198286A1 (en) * | 2008-02-05 | 2009-08-06 | Zimmer, Inc. | Bone fracture fixation system |
AU2008351422A1 (en) * | 2008-02-27 | 2009-09-03 | Allergan, Inc. | Dapsone to treat rosascea |
WO2009126967A1 (en) * | 2008-04-11 | 2009-10-15 | Pediadermics, Llc | Systems and methods for treatment kits |
AU2009240513B2 (en) | 2008-04-24 | 2015-03-26 | Medtronic, Inc. | Chitosan-containing protective composition |
JP5833919B2 (en) | 2008-04-24 | 2015-12-16 | メドトロニック,インコーポレイテッド | Protective gel based on chitosan and oxidized polysaccharide |
US8653319B2 (en) | 2008-04-24 | 2014-02-18 | Medtronic, Inc. | Cold ionizing radiation sterilization |
CA2722145A1 (en) | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Rehydratable thiolated polysaccharide particles and sponge |
US8506944B2 (en) * | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
CN105664136A (en) | 2008-05-07 | 2016-06-15 | 加利福尼亚大学董事会 | Replenishment and Enrichment of Ocular Surface Lubrication |
US7998192B2 (en) * | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8389583B2 (en) | 2008-05-23 | 2013-03-05 | Zurex Pharma, Inc. | Antimicrobial compositions and methods of use |
US8236046B2 (en) * | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US20100004733A1 (en) * | 2008-07-02 | 2010-01-07 | Boston Scientific Scimed, Inc. | Implants Including Fractal Structures |
IT1391669B1 (en) * | 2008-07-23 | 2012-01-17 | Universita' Degli Studi Di Trieste | NANOCOMPOSITE MATERIALS FORMED FROM A POLYSACCHARIDIC MATRIX AND METALLIC NANOPARTICLES, THEIR PREPARATION AND USE |
US7985252B2 (en) * | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US20100030170A1 (en) * | 2008-08-01 | 2010-02-04 | Keith Alan Keller | Absorptive Pad |
US20100082088A1 (en) * | 2008-08-27 | 2010-04-01 | Ali Fassih | Treatment of sweating and hyperhydrosis |
US8150525B2 (en) * | 2008-08-27 | 2012-04-03 | Johnson & Johnson Consumer Companies, Inc. | Treatment of hyperhydrosis |
US20110207807A1 (en) * | 2008-09-02 | 2011-08-25 | Catholic University Industry Academy Cooperation Foundation | New use for homoisoflavone or a salt thereof |
US8382824B2 (en) * | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
EP2218447B1 (en) * | 2008-11-04 | 2017-04-19 | PharmaSol GmbH | Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles |
US20100124568A1 (en) * | 2008-11-20 | 2010-05-20 | Med-Eez, Inc | Pharmaceutical articles coated with lubricious coatings |
US8551517B2 (en) * | 2008-12-16 | 2013-10-08 | Kimberly-Clark Worldwide, Inc. | Substrates providing multiple releases of active agents |
WO2010085753A1 (en) | 2009-01-23 | 2010-07-29 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
WO2010101901A2 (en) * | 2009-03-02 | 2010-09-10 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US9149567B2 (en) * | 2009-03-11 | 2015-10-06 | Ansell Limited | Powder-free antimicrobial coated glove |
US20100229282A1 (en) * | 2009-03-11 | 2010-09-16 | Ansell Limited | Powder-Free Anti-Blocking Coated Glove |
EP2229980B1 (en) * | 2009-03-16 | 2015-08-12 | Nuvolase, Inc. | Treatment of microbiological pathogens in a toe nail with antimicrobial light |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
CA2974972C (en) * | 2009-05-26 | 2018-12-04 | The General Hospital Corporation | Method and apparatus for dermal delivery of a substance |
US9192626B2 (en) * | 2009-06-10 | 2015-11-24 | American Silver, Llc | Dental uses of silver hydrosol |
US8821455B2 (en) * | 2009-07-09 | 2014-09-02 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
US20110008271A1 (en) * | 2009-07-13 | 2011-01-13 | Jr Chem, Llc | Rosacea treatments using polymetal complexes |
US8814922B2 (en) * | 2009-07-22 | 2014-08-26 | New Star Lasers, Inc. | Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure |
US20110022158A1 (en) * | 2009-07-22 | 2011-01-27 | Boston Scientific Scimed, Inc. | Bioerodible Medical Implants |
US20110065798A1 (en) * | 2009-09-17 | 2011-03-17 | Becton, Dickinson And Company | Anti-infective lubricant for medical devices and methods for preparing the same |
US20110091571A1 (en) * | 2009-10-16 | 2011-04-21 | Moore Michael F | Method of controlling the propagation of mrsa, staph and other infections that colonize in the nose |
JP2013509963A (en) | 2009-11-09 | 2013-03-21 | スポットライト テクノロジー パートナーズ エルエルシー | Fragmented hydrogel |
WO2011057131A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
KR20120091335A (en) | 2009-11-13 | 2012-08-17 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Galvanic skin treatment device |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
JP2011135009A (en) * | 2009-12-25 | 2011-07-07 | Tokyo Electron Ltd | Method and apparatus for drying substrate |
KR20110091461A (en) * | 2010-02-05 | 2011-08-11 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Lip compositions comprising galvanic particulates |
CN102781406B (en) * | 2010-03-01 | 2015-07-08 | 强生消费者公司 | Skin care composition having desirable bulk color |
US8668732B2 (en) * | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US20110236491A1 (en) * | 2010-03-25 | 2011-09-29 | Jeannette Chantalat | Topical anti-inflammatory composition |
US9999702B2 (en) | 2010-04-09 | 2018-06-19 | Kci Licensing Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
US20110301553A1 (en) * | 2010-06-04 | 2011-12-08 | Smiths Medical Asd, Inc. | Antimicrobial lubricant |
JP5646277B2 (en) * | 2010-10-25 | 2014-12-24 | クラシエホームプロダクツ株式会社 | Disinfectant and acne treatment / prevention agent |
US9572329B2 (en) * | 2010-11-18 | 2017-02-21 | Samuel P Hopkins | Antimicrobial containing fish hook and method of using and manufacturing same |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
KR20230160959A (en) | 2011-02-16 | 2023-11-24 | 더 제너럴 하스피탈 코포레이션 | Optical coupler for an endoscope |
US9707375B2 (en) | 2011-03-14 | 2017-07-18 | Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. | Catheter grip and method |
US8597264B2 (en) | 2011-03-24 | 2013-12-03 | Kci Licensing, Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
JPWO2012131931A1 (en) * | 2011-03-30 | 2014-07-24 | ダイワボウホールディングス株式会社 | Wound dressing |
WO2012135743A2 (en) | 2011-03-30 | 2012-10-04 | Gr Intellectual Reserve, Llc | Novel gold-platinum based bi-metallic nanocrystal suspensions, electrochemical manufacturing processes therefor and uses for the same |
GB2497115A (en) * | 2011-12-01 | 2013-06-05 | Lrc Products | Coated condom |
JP6017883B2 (en) * | 2012-08-08 | 2016-11-02 | バイオエポック株式会社 | Manufacturing method of toothpaste |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
CN102872159A (en) * | 2012-09-29 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver chitosan gel foam preparation for treating vaginal bacterial inflammation, and preparation method thereof |
CN102872160A (en) * | 2012-10-26 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver foaming agent used for sterilizing wounds of scalds and burns and ulcer wounds |
US10092728B2 (en) | 2012-11-20 | 2018-10-09 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Sheath for securing urinary catheter |
US9872969B2 (en) | 2012-11-20 | 2018-01-23 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Catheter in bag without additional packaging |
US20140377318A1 (en) * | 2012-12-06 | 2014-12-25 | S. Douglas Cornell | Antimicrobial sanitizer systems and methods of killing or inhibiting pathogens |
EP2764876A1 (en) * | 2013-02-11 | 2014-08-13 | Lacerta Technologies Inc. | Bone substitute material with biologically active coating |
US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
GB2511528A (en) | 2013-03-06 | 2014-09-10 | Speciality Fibres And Materials Ltd | Absorbent materials |
US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
JP2016514024A (en) | 2013-03-14 | 2016-05-19 | ハラックス,インコーポレイテッド | How to treat nail infections, diseases or disorders |
EP2976095B1 (en) * | 2013-03-15 | 2020-12-23 | 3M Innovative Properties Company | Wound healing compositions |
US11000545B2 (en) | 2013-03-15 | 2021-05-11 | Cda Research Group, Inc. | Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza |
US10398733B2 (en) | 2013-03-15 | 2019-09-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body |
US11318089B2 (en) | 2013-03-15 | 2022-05-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body |
US11007143B2 (en) | 2013-03-15 | 2021-05-18 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body |
US11083750B2 (en) | 2013-03-15 | 2021-08-10 | Cda Research Group, Inc. | Methods of treatment using topical copper ion formulations |
US20140271919A1 (en) * | 2013-03-15 | 2014-09-18 | Chun Lim Abbott | Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Genital-Rectal Areas of the Body |
US9095566B1 (en) * | 2013-06-28 | 2015-08-04 | Edward Quicksilver Yavitz | Eyelash and eyelid margin infections |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US20150182673A1 (en) | 2013-12-30 | 2015-07-02 | Boston Scientific Scimed, Inc. | Functionalized lubricious medical device coatings |
CN104814831A (en) * | 2014-01-30 | 2015-08-05 | 柯惠有限合伙公司 | Preparation of occlusive dressings |
US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
KR102462510B1 (en) * | 2014-08-26 | 2022-11-01 | 씨. 알. 바드, 인크. | Urinary catheter |
US9459442B2 (en) | 2014-09-23 | 2016-10-04 | Scott Miller | Optical coupler for optical imaging visualization device |
CN104577135B (en) * | 2015-01-04 | 2017-01-18 | 哈尔滨工业大学 | Preparation method of three-dimensional silver mesh |
US10548467B2 (en) | 2015-06-02 | 2020-02-04 | GI Scientific, LLC | Conductive optical element |
US10856724B2 (en) | 2015-07-21 | 2020-12-08 | GI Scientific, LLC | Endoscope accessory with angularly adjustable exit portal |
RU2611999C2 (en) * | 2015-08-05 | 2017-03-01 | Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук | Silver nanocomposite based on arabinogalactan conjugate and flavonoids with antimicrobial and antitumor action and preparation method thereof |
US10040957B2 (en) * | 2015-09-17 | 2018-08-07 | Eastman Kodak Company | Ink jettable, UV-curable compositions |
DE102015115878B4 (en) * | 2015-09-21 | 2018-03-29 | Aap Implantate Ag | A method of treating a metallic surface and bodies having a treated metallic surface |
US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
CN114225119A (en) * | 2016-02-08 | 2022-03-25 | 祥丰医疗私人有限公司 | Expandable balloon comprising a coating |
US10792477B2 (en) | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
US11330931B2 (en) | 2016-09-29 | 2022-05-17 | Levo Oil Infusion | Apparatus and method for infusing and dispensing oils, and drying and heating infusing materials |
CN111107812A (en) | 2017-09-19 | 2020-05-05 | C·R·巴德股份有限公司 | Catheter bridging apparatus, system and method thereof |
RU2659580C1 (en) * | 2017-10-16 | 2018-07-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) | Method for obtaining agent for topical treatment of skin lesions based on nanoscale silver particles, ointment base and solid additives |
US10912739B2 (en) | 2017-10-16 | 2021-02-09 | Peace Out Inc. | Hydrocolloid-based skin treatment |
WO2020006073A1 (en) | 2018-06-28 | 2020-01-02 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
CN108853557A (en) * | 2018-07-23 | 2018-11-23 | 衢州玛济克医疗科技有限公司 | A kind of wet erythema medical dressing of infant and its production method |
CN109646456A (en) * | 2018-12-31 | 2019-04-19 | 四川金凯医疗器械有限公司 | It is a kind of for treating the new type gel of periodontitis |
US11193184B2 (en) | 2019-02-22 | 2021-12-07 | Cda Research Group, Inc. | System for use in producing a metal ion suspension and process of using same |
RU2730480C1 (en) * | 2019-07-30 | 2020-08-24 | Общество с ограниченной ответственностью "БиоМед" | Method of administering a pharmaceutical substance into a polymer substrate of a dressing |
WO2021202332A1 (en) * | 2020-03-28 | 2021-10-07 | Iview Therapeutics, Inc. | Aqueous formulations containing povidone iodine for effective treatment and prevention of virus infections |
DE102021205475A1 (en) | 2021-05-28 | 2022-12-01 | FNT-GmbH | Antimicrobial composition, method of making an antimicrobial composition and use of an antimicrobial composition |
CN113479975A (en) * | 2021-07-01 | 2021-10-08 | 辽宁锦海医药科技有限公司 | Preparation method and application of oxidation potential acidic water |
WO2023101440A1 (en) * | 2021-11-30 | 2023-06-08 | 경희대학교 산학협력단 | Anti-inflammatory composition, containing extract of gold nanoparticle-peanut sprout as active ingredient |
US11684586B1 (en) | 2022-02-28 | 2023-06-27 | Peace Out, Llc | Anhydrous hydrocolloid matrix comprising homogeneously distributed encapsulated therapeutic agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013704A1 (en) | 1993-11-18 | 1995-05-26 | Westaim Technologies Inc. | Anti-microbial materials |
WO1998041095A2 (en) | 1997-03-17 | 1998-09-24 | Westaim Technologies Inc. | Anti-microbial coatings having indicator properties and wound dressings |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB420052A (en) | 1932-10-17 | 1934-11-23 | Consortium Elektrochem Ind | Manufacture of shaped articles from polyvinyl alcohols |
FR732895A (en) | 1932-10-18 | 1932-09-25 | Consortium Elektrochem Ind | Articles spun in polyvinyl alcohol |
FR882M (en) | 1961-01-18 | 1961-10-06 | ||
GB1270410A (en) | 1969-09-25 | 1972-04-12 | Allor Corp | Colloidal composition and method of preparing the same |
US3757786A (en) | 1970-11-06 | 1973-09-11 | D Smith | Synthetic surgical sutures |
US3800792A (en) | 1972-04-17 | 1974-04-02 | Johnson & Johnson | Laminated collagen film dressing |
US3988434A (en) * | 1972-08-07 | 1976-10-26 | Schole Murray L | Dental preparation |
US3918446A (en) | 1974-05-03 | 1975-11-11 | E Med Corp | Securement device for intravenous catheter and its tubing |
US4059105A (en) * | 1976-03-24 | 1977-11-22 | Omnimed, Inc. | Cannula securing device |
DE2748882A1 (en) | 1977-11-02 | 1979-05-03 | Arnis Dr Med Rava | Plaster protecting wound against infection - esp. during application of intravenous catheter, permitting continuous use for ten days |
DE2929706C2 (en) * | 1979-07-21 | 1982-09-30 | Drägerwerk AG, 2400 Lübeck | Breathing air humidifiers and warmers for ventilation systems |
US4324237A (en) * | 1980-02-26 | 1982-04-13 | E-Med Corporation | Intravenous catheter and tubing securement and dressing device with a window over the puncture or wound site |
GB2073024B (en) | 1980-03-27 | 1984-06-27 | Nat Res Dev | Antimicrobial surgical implants |
JPS57500588A (en) | 1980-03-27 | 1982-04-08 | ||
DE3176658D1 (en) * | 1981-12-10 | 1988-03-31 | Revlon | Process for making metallic leafing pigments |
JPS58126910A (en) | 1982-01-21 | 1983-07-28 | Nippon Steel Corp | Dephosphorizing method of molten metal |
GB2140684B (en) | 1983-04-25 | 1986-07-30 | Stavros Christodoulou | Mineral oil composition for use in the treatment of eczema |
JPS6021912A (en) | 1983-07-14 | 1985-02-04 | Mitsubishi Rayon Co Ltd | Manufacture of metallized synthetic fiber staple |
US4828832A (en) * | 1983-09-07 | 1989-05-09 | Laboratorios Biochemie De Mexico | Method of manufacturing a composition for treating skin lesions |
EP0136768A3 (en) | 1983-09-07 | 1986-07-30 | Laboratorios Biochemie De Mexico S.A. DE C.V. | Composition and method for treatingskin lesions |
US4581028A (en) | 1984-04-30 | 1986-04-08 | The Trustees Of Columbia University In The City Of New York | Infection-resistant materials and method of making same through use of sulfonamides |
GB8421706D0 (en) | 1984-08-28 | 1984-10-03 | Pharmaceutical Holdings Ltd | Pharmaceutical preparations |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4633863A (en) | 1985-09-27 | 1987-01-06 | Filips Chester P | Arterial anchor bandage |
US4960413A (en) | 1985-11-09 | 1990-10-02 | The Shirley Institute | Wound dressing |
US5122418A (en) | 1985-12-09 | 1992-06-16 | Shiseido Company Ltd. | Composite powder and production process |
US4847049A (en) * | 1985-12-18 | 1989-07-11 | Vitaphore Corporation | Method of forming chelated collagen having bactericidal properties |
JPS62185807A (en) | 1986-02-08 | 1987-08-14 | Mitsubishi Shindo Kk | Production of metallic flat powder |
GB8607159D0 (en) | 1986-03-22 | 1986-04-30 | Smith & Nephew Ass | Pharmaceutical composition |
GB8612598D0 (en) | 1986-05-23 | 1986-07-02 | Tarnpure Ltd | Liquid/gas interface apparatus |
US5236421A (en) | 1986-05-28 | 1993-08-17 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Fixing system for fastening catheters, cannulas or the like to the skin surface and process for the sterile fastening thereof |
EP0254413A3 (en) | 1986-06-13 | 1989-11-08 | Yoshiaki Matsuo | Silver-ionic water and its uses |
US4952411A (en) | 1987-02-25 | 1990-08-28 | Trustees Of Columbia University In The City Of New York | Method of inhibiting the transmission of AIDS virus |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5143717A (en) | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
US5019096A (en) | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
DE3807944A1 (en) | 1988-03-10 | 1989-09-21 | Braun Melsungen Ag | Device for fastening a catheter or a cannula on the skin surface |
NZ228367A (en) * | 1988-03-23 | 1992-02-25 | Smithkline Beecham Corp | Topical composition containing a gold compound for treating inflammatory conditions |
US4956350A (en) | 1988-08-18 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Wound filling compositions |
AU4045489A (en) | 1988-08-18 | 1990-03-23 | Konrad Minninger | Silver sulfadiazine containing pharmaceutical product for the local external therapy |
US4908355A (en) | 1989-01-09 | 1990-03-13 | Dow Corning Corporation | Skin treatment method |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5270358A (en) | 1989-12-28 | 1993-12-14 | Minnesota Mining And Manufacturing Company | Composite of a disperesed gel in an adhesive matrix |
JP3169621B2 (en) | 1991-01-29 | 2001-05-28 | 株式会社タカミツ | Antimicrobial external preparation |
EP0570452A1 (en) | 1991-02-06 | 1993-11-24 | Minnesota Mining And Manufacturing Company | Improved surgical hardware with bacteriostatic silver coating, and method of using same |
US5484886A (en) * | 1991-04-25 | 1996-01-16 | Merck & Co., Inc. | Human neurokinin-1 receptor |
US5348799A (en) | 1991-09-03 | 1994-09-20 | Minnesota Mining And Manufacturing Company | Antistatic coatings comprising chitosan acid salt and metal oxide particles |
GEP20002074B (en) | 1992-05-19 | 2000-05-10 | Westaim Tech Inc Ca | Modified Material and Method for its Production |
US5681575A (en) * | 1992-05-19 | 1997-10-28 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
USD349958S (en) | 1992-07-24 | 1994-08-23 | Bioject Inc. | Needleless injector |
CN1034090C (en) | 1992-08-06 | 1997-02-19 | 蒋建华 | Long-acting broad-spectrum antiseptic fabric and its producing method |
IT1256111B (en) | 1992-11-23 | 1995-11-28 | Lifegroup Spa | SALTS OF TRAUMATIC ACID WITH CICATRIZING AND ANTIBACTERIAL ACTIVITY |
JP2981528B2 (en) | 1992-12-25 | 1999-11-22 | 三菱電機株式会社 | Cathode ray tube and method of manufacturing the same |
JP3513199B2 (en) * | 1993-01-01 | 2004-03-31 | キヤノン株式会社 | Liquid ejecting head, liquid ejecting head cartridge and recording apparatus using the same, and method of manufacturing liquid ejecting head |
US5631066A (en) | 1993-01-25 | 1997-05-20 | Chronopol, Inc. | Process for making metalized films and films produced therefrom |
US5534288A (en) | 1993-03-23 | 1996-07-09 | United States Surgical Corporation | Infection-resistant surgical devices and methods of making them |
US5848995A (en) | 1993-04-09 | 1998-12-15 | Walder; Anthony J. | Anti-infective medical article and method for its preparation |
US5454889A (en) * | 1993-08-19 | 1995-10-03 | Ici Canada Inc. | Prill coating |
WO1995012602A1 (en) | 1993-11-05 | 1995-05-11 | Meiji Milk Products Co., Ltd. | Antibacterial, antifungal and antiviral agent |
US5454886A (en) * | 1993-11-18 | 1995-10-03 | Westaim Technologies Inc. | Process of activating anti-microbial materials |
US5372589A (en) | 1993-11-24 | 1994-12-13 | Davis; W. Gordon | Fenestrated transparent catheter securing device and method |
EP0681841A1 (en) | 1993-11-26 | 1995-11-15 | Kimurakogyo Co., Ltd. | $i(IN VIVO) FREE-RADICAL GENERATOR |
US5817325A (en) | 1996-10-28 | 1998-10-06 | Biopolymerix, Inc. | Contact-killing antimicrobial devices |
JPH07220702A (en) * | 1994-02-02 | 1995-08-18 | Nec Corp | Battery pack |
CA2184828C (en) | 1994-03-28 | 2008-08-12 | Shanta M. Modak | Composition for inactivating irritants in fluids |
US5899880A (en) | 1994-04-08 | 1999-05-04 | Powderject Research Limited | Needleless syringe using supersonic gas flow for particle delivery |
US5563132A (en) | 1994-06-21 | 1996-10-08 | Bodaness; Richard S. | Two-step cancer treatment method |
WO1996004409A1 (en) * | 1994-08-01 | 1996-02-15 | Franz Hehmann | Selected processing for non-equilibrium light alloys and products |
US5578073A (en) | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5569207A (en) * | 1994-10-13 | 1996-10-29 | Quinton Instrument Company | Hydrocolloid dressing |
GB9424562D0 (en) | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
US5589177A (en) | 1994-12-06 | 1996-12-31 | Helene Curtis, Inc. | Rinse-off water-in-oil-in-water compositions |
GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
JP3977422B2 (en) | 1995-06-07 | 2007-09-19 | エス. ニューワース,ロバート | Methods and compositions for chemical necrosis in utero |
US5744151A (en) * | 1995-06-30 | 1998-04-28 | Capelli; Christopher C. | Silver-based pharmaceutical compositions |
US6013050A (en) | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
DE19541735A1 (en) | 1995-11-09 | 1997-05-15 | Iris Roller | Use of hydrothermal rock deposits e.g. calcite precursors |
US5686096A (en) | 1995-12-22 | 1997-11-11 | Becton Dickinson And Company | Medical device for the protection of a catheter penetration site |
DE69728678T2 (en) | 1996-07-11 | 2005-04-21 | Coloplast As | HYDROCOLLOID-WOUND GEL |
US5895419A (en) | 1996-09-30 | 1999-04-20 | St. Jude Medical, Inc. | Coated prosthetic cardiac device |
DE19640365A1 (en) | 1996-09-30 | 1998-04-02 | Basf Ag | Polymer-hydrogen peroxide complexes |
EP0834319A1 (en) * | 1996-10-07 | 1998-04-08 | Kartar Dr. Lalvani | Mineral and vitamin combinations in arthritic pain |
GB9623962D0 (en) * | 1996-11-15 | 1997-01-08 | Tillotts Pharma Ag | Pharmaceutical composition |
US6277169B1 (en) | 1997-02-24 | 2001-08-21 | Superior Micropowders Llc | Method for making silver-containing particles |
GB2324732B (en) | 1997-05-02 | 2001-09-26 | Johnson & Johnson Medical | Absorbent wound dressings |
WO1998051273A1 (en) | 1997-05-12 | 1998-11-19 | Sage Pharmaceuticals, Inc. | Topical spray for burn treatment and anti-infection |
US6071543A (en) | 1997-06-02 | 2000-06-06 | Cellegy Pharmaceuticals, Inc. | Pyridine-thiols reverse mucocutaneous aging |
KR20010013377A (en) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | Mild, leave-on antimicrobial compositions |
DK0991702T3 (en) | 1997-06-20 | 2001-12-03 | Coloplast As | Hydrophilic coating |
DE19728489A1 (en) | 1997-07-03 | 1999-01-07 | Huels Chemische Werke Ag | Medical device for improving the skin fixation of indwelling catheters and other transcutaneous implants with a reduced risk of infection |
US6165440A (en) | 1997-07-09 | 2000-12-26 | Board Of Regents, The University Of Texas System | Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
US6153210A (en) * | 1997-08-14 | 2000-11-28 | Periodontix, Inc. | Use of locally delivered metal ions for treatment of periodontal disease |
JP3411195B2 (en) * | 1997-08-18 | 2003-05-26 | 栄一 築地 | Active oxygen remover |
JPH11116488A (en) | 1997-10-08 | 1999-04-27 | Toagosei Co Ltd | Carcinostatic agent |
JP4039719B2 (en) * | 1997-10-17 | 2008-01-30 | 富士フイルム株式会社 | Antitumor agent |
US6312643B1 (en) * | 1997-10-24 | 2001-11-06 | The United States Of America As Represented By The Secretary Of The Air Force | Synthesis of nanoscale aluminum alloy powders and devices therefrom |
HU221676B1 (en) * | 1998-02-20 | 2002-12-28 | István Budai | Pharmaceutical composition, containing ethanol or water-ethanol solution having iodine and silver nitrate and process for producing it |
FR2775696B1 (en) * | 1998-03-05 | 2000-04-14 | Saint Gobain Vitrage | SUBSTRATE WITH PHOTOCATALYTIC COATING |
US20020014406A1 (en) * | 1998-05-21 | 2002-02-07 | Hiroshi Takashima | Aluminum target material for sputtering and method for producing same |
US6123925A (en) | 1998-07-27 | 2000-09-26 | Healthshield Technologies L.L.C. | Antibiotic toothpaste |
US6071541A (en) * | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
CN1273638C (en) * | 1998-10-23 | 2006-09-06 | 艾弗里·丹尼森公司 | Process for making metal flakes |
US6238986B1 (en) * | 1998-11-06 | 2001-05-29 | Advanced Micro Devices, Inc. | Formation of junctions by diffusion from a doped film at silicidation |
WO2000027390A1 (en) * | 1998-11-09 | 2000-05-18 | Ira Jay Newman | Ionic silver complex |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
US6436422B1 (en) | 1998-11-23 | 2002-08-20 | Agion Technologies L.L.C. | Antibiotic hydrophilic polymer coating |
US6365130B1 (en) | 1998-11-23 | 2002-04-02 | Agion Technologies L.L.C. | Antimicrobial chewing gum |
US6224579B1 (en) | 1999-03-31 | 2001-05-01 | The Trustees Of Columbia University In The City Of New York | Triclosan and silver compound containing medical devices |
US6258385B1 (en) | 1999-04-22 | 2001-07-10 | Marantech Holding, Llc | Tetrasilver tetroxide treatment for skin conditions |
JP4454062B2 (en) | 1999-05-17 | 2010-04-21 | 敬 三宅 | Ultrafine particle silver milky body and method for producing the same |
EP1066825A1 (en) * | 1999-06-17 | 2001-01-10 | The Procter & Gamble Company | An anti-microbial body care product |
CN1161511C (en) | 1999-07-27 | 2004-08-11 | 蒋建华 | Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method |
JP2001151681A (en) | 1999-11-24 | 2001-06-05 | Lintec Corp | Prophylactic and/or therapeutic agent for systema digestorium disease |
CN1108786C (en) | 1999-12-28 | 2003-05-21 | 天津市化妆品科学技术研究所 | Silver foil cosmetics |
JP2003519188A (en) * | 2000-01-06 | 2003-06-17 | マランテック ホールディング リミテッド ライアビリティ カンパニー | Compositions and methods for promoting skin growth and treating skin conditions |
US7137968B1 (en) | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
US6224898B1 (en) | 2000-03-23 | 2001-05-01 | The United States Of America As Represented By The Secretary Of The Army | Antimicrobial dendrimer nanocomposites and a method of treating wounds |
US6719987B2 (en) * | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
SE516537C2 (en) * | 2000-05-19 | 2002-01-29 | Alfa Laval Ab | Flat pack and plate heat exchanger |
US6592888B1 (en) | 2000-05-31 | 2003-07-15 | Jentec, Inc. | Composition for wound dressings safely using metallic compounds to produce anti-microbial properties |
PT1395289E (en) * | 2000-06-08 | 2011-03-16 | Sang Dr Christine | Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists |
US7008647B2 (en) * | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
AU7832201A (en) | 2000-07-27 | 2002-02-13 | Nucryst Pharm Corp | Treatment of hyperproliferative skin disorders and diseases |
US20030170314A1 (en) * | 2000-07-27 | 2003-09-11 | Burrell Robert E. | Compositions of metal-containing compounds |
DE10037353A1 (en) | 2000-07-29 | 2002-02-07 | Hans E Sachse | Catheter with bioabsorbable coating to prevent rising infections |
CN1279222A (en) | 2000-07-31 | 2001-01-10 | 金华尖峰陶瓷有限责任公司 | Antibacterial inorganic ceramics and its production technology |
CN1291667A (en) | 2000-08-14 | 2001-04-18 | 骏安科技投资有限公司 | Nanometer silver anti-bacteria cloth and its industrial production technology |
CN1147640C (en) | 2000-09-19 | 2004-04-28 | 南京希科集团有限公司 | Antibacterial fabric containing nm-class silver powder and its making method |
CN1159488C (en) | 2001-01-20 | 2004-07-28 | 南京希科集团有限公司 | Antibacterial flexible material containing nm silver and its preparing process and application |
CN1179646C (en) | 2001-04-20 | 2004-12-15 | 朱红军 | Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process |
WO2002085386A2 (en) * | 2001-04-23 | 2002-10-31 | Nucryst Pharmaceuticals Corp. | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
CN1183285C (en) | 2001-04-25 | 2005-01-05 | 朱红军 | Aggregation-preventing wide-spectrum nanometer antibiotic silver yarn and its industrial production process |
-
2002
- 2002-04-23 WO PCT/CA2002/000548 patent/WO2002085386A2/en not_active Application Discontinuation
- 2002-04-23 WO PCT/CA2002/000546 patent/WO2002085384A2/en not_active Application Discontinuation
- 2002-04-23 CA CA002445734A patent/CA2445734A1/en not_active Abandoned
- 2002-04-23 DE DE2002610441 patent/DE60210441T2/en not_active Expired - Lifetime
- 2002-04-23 US US10/128,208 patent/US6989156B2/en not_active Expired - Fee Related
- 2002-04-23 JP JP2002582960A patent/JP2004529930A/en active Pending
- 2002-04-23 AT AT02721904T patent/ATE322274T1/en active
- 2002-04-23 CA CA 2445740 patent/CA2445740A1/en not_active Abandoned
- 2002-04-23 US US10/131,568 patent/US20030021854A1/en not_active Abandoned
- 2002-04-23 WO PCT/CA2002/000549 patent/WO2002085387A2/en active IP Right Grant
- 2002-04-23 JP JP2002582875A patent/JP2005507368A/en active Pending
- 2002-04-23 JP JP2002582959A patent/JP2004529929A/en active Pending
- 2002-04-23 EP EP20020721903 patent/EP1383521A2/en not_active Withdrawn
- 2002-04-23 AU AU2002252881A patent/AU2002252881B2/en not_active Ceased
- 2002-04-23 EP EP20020721904 patent/EP1383522B1/en not_active Expired - Lifetime
- 2002-04-23 WO PCT/US2002/012690 patent/WO2002085299A2/en active Search and Examination
- 2002-04-23 US US10/131,511 patent/US6939568B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,509 patent/US7087249B2/en not_active Expired - Lifetime
- 2002-04-23 CA CA002443587A patent/CA2443587A1/en not_active Abandoned
- 2002-04-23 AU AU2002249046A patent/AU2002249046A1/en not_active Abandoned
- 2002-04-23 EP EP02721902.1A patent/EP1383520B1/en not_active Expired - Lifetime
- 2002-04-23 ES ES02721904T patent/ES2261659T3/en not_active Expired - Lifetime
- 2002-04-23 CA CA 2445729 patent/CA2445729C/en not_active Expired - Fee Related
- 2002-04-23 AU AU2002252879A patent/AU2002252879B2/en not_active Ceased
- 2002-04-23 EP EP02731461A patent/EP1390013A4/en not_active Withdrawn
- 2002-04-23 US US10/131,513 patent/US6723350B2/en not_active Expired - Lifetime
- 2002-04-23 WO PCT/CA2002/000547 patent/WO2002085385A2/en active IP Right Grant
- 2002-04-23 AU AU2002303438A patent/AU2002303438B2/en not_active Ceased
- 2002-04-23 JP JP2002582958A patent/JP2004525980A/en active Pending
-
2004
- 2004-02-05 US US10/772,672 patent/US20040157073A1/en not_active Abandoned
-
2005
- 2005-07-01 US US11/174,104 patent/US20050271743A1/en not_active Abandoned
- 2005-11-22 US US11/284,507 patent/US20060083792A1/en not_active Abandoned
-
2006
- 2006-05-16 US US11/434,958 patent/US20060204591A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013704A1 (en) | 1993-11-18 | 1995-05-26 | Westaim Technologies Inc. | Anti-microbial materials |
WO1998041095A2 (en) | 1997-03-17 | 1998-09-24 | Westaim Technologies Inc. | Anti-microbial coatings having indicator properties and wound dressings |
Non-Patent Citations (2)
Title |
---|
J.A. THORNTON: "Influence of Apparatus Geometry and Deposition Conditions on the Structure and Topography of Thick Sputtered Coatings", J. VAC. SCI. TECHNOL., vol. 11, no. 4, 1974, pages 666 - 670, XP000998787, DOI: doi:10.1116/1.1312732 |
R. P. ANDRES ET AL.: "Research Opportunities on Cluster and Cluster-Assembled Materials", I. MATER. RES., vol. 4, no. 3, 1989, pages 704 |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8735644B2 (en) | 2001-02-16 | 2014-05-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8163974B2 (en) | 2001-02-16 | 2012-04-24 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8084664B2 (en) | 2001-02-16 | 2011-12-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
EP1575552A2 (en) * | 2002-10-22 | 2005-09-21 | Nucryst Pharmaceuticals Corp. | Metal-containing materials, compositions and methods |
EP1575552A4 (en) * | 2002-10-22 | 2011-05-25 | Smith & Nephew Overseas Ltd | Metal-containing materials, compositions and methods |
US8637071B2 (en) | 2002-12-19 | 2014-01-28 | Novartis Ag | Method for making medical devices having antimicrobial coatings thereon |
US8309117B2 (en) | 2002-12-19 | 2012-11-13 | Novartis, Ag | Method for making medical devices having antimicrobial coatings thereon |
WO2004075920A1 (en) * | 2003-02-26 | 2004-09-10 | Otsuka Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition for lung administration |
CN1744917B (en) * | 2003-02-26 | 2010-05-05 | 大塚制药株式会社 | Sustained-release pharmaceutical composition for lung administration |
DE10359338A1 (en) * | 2003-12-17 | 2005-07-21 | Heraeus Kulzer Gmbh | Antimicrobial nanosilver additive for polymerizable dental materials |
DE10359338B4 (en) * | 2003-12-17 | 2007-07-19 | Heraeus Kulzer Gmbh | Antimicrobial nanosilver additive for polymerizable dental materials |
US8519146B2 (en) * | 2004-09-07 | 2013-08-27 | The University Of Akron | Metal complexes of N-heterocyclic carbenes as antibiotics |
EP1842524A1 (en) * | 2004-12-13 | 2007-10-10 | APT Co., Ltd. | Cleaning liquid for oral cavity |
EP1842524B1 (en) * | 2004-12-13 | 2013-01-23 | APT Co., Ltd. | Cleaning liquid for oral cavity |
EP2024117B1 (en) * | 2006-04-24 | 2012-11-14 | Nm Tech Ltd. Nanomaterials And Microdevices Technology | Functional nanomaterials with antibacterial and antiviral activity |
US8158137B2 (en) | 2006-04-24 | 2012-04-17 | NM Tech Nanomaterials and Microdevices Technology Limited | Functional nanomaterials with antibacterial and antiviral activity |
US8178122B2 (en) | 2006-06-14 | 2012-05-15 | Nm Tech Nanomaterials And Microdevices Technology Ltd. | Use of nanomaterials based on titanium dioxide and zirconium diozide as coatings for osteointegrated biomedical prostheses, and osteointegrated biomedical prostheses prepared therewith |
EP2452559A1 (en) * | 2006-10-12 | 2012-05-16 | NM Tech Nanomaterials Microdevice Technology, Ltd. | Material, item and products comprising a composition having anti-microbial properties |
EP2452560A1 (en) * | 2006-10-12 | 2012-05-16 | NM Tech Nanomaterials Microdevice Technology, Ltd. | Material, item and products comprising a composition having anti-microbial properties |
EP2452558A1 (en) * | 2006-10-12 | 2012-05-16 | NM Tech Nanomaterials Microdevice Technology, Ltd. | Material, item and products comprising a composition having anti-microbial properties |
EP2452561A1 (en) * | 2006-10-12 | 2012-05-16 | NM Tech Nanomaterials Microdevice Technology, Ltd. | Material, item and products comprising a composition having anti-microbial properties |
US8389022B2 (en) | 2006-10-12 | 2013-03-05 | Nm Tech Nanomaterials Microdevice Technology Ltd. | Material, item and products comprising a composition having anti-microbial properties |
WO2008043396A1 (en) * | 2006-10-12 | 2008-04-17 | Nm Tech Nanomaterials Microdevice Technology Ltd. | Material, item and products comprising a composition having anti-microbial properties |
US8906883B2 (en) | 2009-06-10 | 2014-12-09 | Exthera Ab | Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate |
RU2452498C2 (en) * | 2010-07-20 | 2012-06-10 | Общество с ограниченной ответственностью "Научно-производственное объединение "Ликом" | Method for preparing anti-tuberculosis drug |
US8802154B2 (en) | 2010-08-27 | 2014-08-12 | Sienna Labs, Inc. | Thermal treatment of a pilosebaceous unit with nanoparticles |
US8821940B2 (en) | 2010-08-27 | 2014-09-02 | Sienna Labs, Inc. | Thermal treatment of the skin surface with nanoparticles |
US8821941B2 (en) | 2010-08-27 | 2014-09-02 | Sienna Labs, Inc. | Hair removal with nanoparticles |
US8834933B2 (en) | 2010-08-27 | 2014-09-16 | Sienna Labs, Inc. | Thermal treatment of acne with nanoparticles |
US8895071B1 (en) | 2010-08-27 | 2014-11-25 | Sienna Labs, Inc. | Thermal treatment of a pilosebaceous unit with coated metal nanoparticles |
US11826087B2 (en) | 2010-08-27 | 2023-11-28 | Coronado Aesthetics, Llc | Compositions and methods for thermal skin treatment with metal nanoparticles |
US8906418B1 (en) | 2010-08-27 | 2014-12-09 | Sienna Labs, Inc. | Thermal treatment of a pilosebaceous unit with nanoparticles with coatings that facilitate selective removal from the skin surface |
US9061056B2 (en) | 2010-08-27 | 2015-06-23 | Sienna Labs, Inc. | Compositions and methods for targeted thermomodulation |
US11419937B2 (en) | 2010-08-27 | 2022-08-23 | Coronado Aesthetics, Llc | Delivery of nanoparticles |
US10537640B2 (en) | 2010-08-27 | 2020-01-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
US10688126B2 (en) | 2012-10-11 | 2020-06-23 | Nanocomposix, Inc. | Silver nanoplate compositions and methods |
US11583553B2 (en) | 2012-10-11 | 2023-02-21 | Nanocomposix, Llc | Silver nanoplate compositions and methods |
WO2014066850A2 (en) * | 2012-10-26 | 2014-05-01 | Nanocomposix, Inc. | Metastable silver nanoparticle composites |
WO2014066850A3 (en) * | 2012-10-26 | 2014-07-03 | Nanocomposix, Inc. | Metastable silver nanoparticle composites |
WO2018009998A1 (en) * | 2016-07-14 | 2018-01-18 | Luiz Francisco Pianowski | Antimicrobial mucosal formulation and use of the antimicrobial mucosal formulation |
US10537658B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
US10537661B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
US11058799B2 (en) | 2017-03-28 | 2021-07-13 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
US11141505B2 (en) | 2017-03-28 | 2021-10-12 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
US11793907B2 (en) | 2017-03-28 | 2023-10-24 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
US11793910B2 (en) | 2017-03-28 | 2023-10-24 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
CN109731103A (en) * | 2019-01-20 | 2019-05-10 | 桂林理工大学 | P-zeolite-chitin-sodium alginate-potassium diformate sustained-release antibacterial agent preparation method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2445729C (en) | Use of metals to treat mucosal membranes | |
AU2002252879A1 (en) | Use of metals to treat mucosal membranes | |
US7255881B2 (en) | Metal-containing materials | |
US6989157B2 (en) | Dry powders of metal-containing compounds | |
US7470437B2 (en) | Methods of treating conditions with a metal-containing material | |
US20030170314A1 (en) | Compositions of metal-containing compounds | |
AU2002303438A1 (en) | Therapeutic treatments using the direct application of antimicrobial metal compositions | |
US7201925B2 (en) | Treatment of ungual and subungual diseases | |
US7078060B2 (en) | Solutions and aerosols of metal-containing compounds | |
US7001617B2 (en) | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals | |
US20040191329A1 (en) | Compositions and methods of metal-containing materials | |
US20030194444A1 (en) | Methods of treating skin and integument conditions | |
US7427416B2 (en) | Methods of treating conditions using metal-containing materials | |
US20030206966A1 (en) | Methods of inducing apoptosis and modulating metalloproteinases | |
US20060115541A1 (en) | Treatment of bladder conditions | |
EP1575552A2 (en) | Metal-containing materials, compositions and methods | |
AU2002252880A1 (en) | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002252879 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2445729 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002582958 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002721902 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002721902 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002252879 Country of ref document: AU |